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1. Introduction 
1.1 The vertebrate skeleton 
The vertebrate skeleton is a complex organ responsible for several functions 
during vertebrate life. It serves as a scaffold to protect the internal organs such as 
brain, lungs and heart. It is also the site of haematopoiesis that takes place in 
thered bone marrow. Furthermore in the skeleton the bone matrix which contains 
high level of calcium hydroxylapatite serve as regulator for calcium homeostasis. 
The skeleton consists of more than 200 individual elements which are supported 
by ligaments, tendons, muscles and cartilage to ensure the flexibility of 
movements. Skeletal elements are organized along the longitudinal axis form the 
axial skeleton. This consists of the vertebral column, the thoracic cage and the 
skull. The appendicular skeleton, to which the upper and lower limbs belong, is 
attached by the pectoral and pelvic girdles to the axial skeleton (Cormack, 1987). 
The major types of vertebrate skeletal bones are divided in four categories: 1. long 
(e.g. the arm and leg bones), 2. short (e.g. the small bones in the wrists and 
ankles), 3. flat (e.g. the bones of the skull) and 4. irregular (e.g. vertebrae). Long, 
short, and irregular bones develop by endochondral ossification process and 
cartilage is replaced by bone. Flat bones develop by intramembranous 
ossification, in which bone is formed within sheets of connective tissue. 
1.2 Ossification 
1.2.1 Intramembraneous ossification 
During intramembraneous ossification skeletal elements develop directly from a 
soft connective tissue into mineralized bone. First, mesenchymal cells migrate and 
aggregate into a mesenchymal condensation. These cells differentiate directly into 
osteoblasts, depositing a bone matrix rich in Collagen type 1 (Col1). Membranous 
bones constitute a small percentage of the skeletal elements, including the flat 
bones of the skull, calvaria and mandibles, and parts of the clavicles (Hall, 1988; 
Huang et al., 1997). 
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1.2.2 Endochondral ossification  
Most bones of the vertebrate skeleton develop by endochondral ossification. The 
first phase of endochondral ossification starts around embryonic day 10.5 (E10.5) 
when the mesenchymal condensations are formed, generating the templates of 
the future bones (Hall and Miyake, 2000; Mariani and Martin, 2003). At the time 
that cartilage forms, blood vessels which had occupied the mesenchyme regress 
at the sites of the condensations (Feinberg et al., 1986; Yin and Pacifici, 2001). 
Cells of the early template produce an extracellular matrix (ECM), which is 
consists mainly of Col1. Cells in the center of the skeletal anlagen differentiate into 
chondrocytes, producing an extracellular matrix, rich in Collagen type 2 (Col2) and 
the proteoglycan aggrecan (Agc1) (Horton et al., 1993). Cells in the periphery of 
the anlagen aquire a more elongated shape, continue to produce Col1 and 
differentiate into fibroblast like perichondrial cells (Caplan and Pechak, 1987). 
From about E13.5 on, different chondrocyte subpopulations can morphologically 
be distinguished. At the distal ends of the cartilage anlagen the low proliferating 
chondrocytes have a small and round shape, while towards the center 
chondrocytes increase their proliferation rate, flatten and align into columns along 
the longitudinal axis of the skeletal elements. In the center of the anlagen, 
chondrocytes exit the cell cycle, stop proliferating and differentiate into pre-
hypertrophic and hypertrophic chondrocytes, producing a type X Collagen (ColX) 
rich matrix, typical for this chondrocytes subpopulation (Linsenmayer et al., 1991; 
Poole 1991).  
At this stage, cells in the perichondrium surrounding the hypertrophic 
chondrocytes differentiate into osteoblasts, which mineralize the Col1 rich matrix 
and form the bone collar (Caplan and Pechak 1987). Vascular invasion of the 
hypertrophic cartilage starts from the bone collar (Vu et al., 1998). Hypertrophic 
chondrocytes differentiate into terminal hypertrophic cells, which express matrix 
metalloprotease 13 (Mmp13) and eventually undergo apoptosis. Mmp13 is a 
collagenase that degrades the hypertrophic cartilage, thereby facilitating the 
invasion of the blood vessels (Ortega et al., 2004). Invading osteoclasts further 
degrade the ColX rich matrix, thereby allowing deposition of a new mineralized 
bone matrix by osteoblasts. The zone of the skeletal anlagen which starts to 
mineralize during chondrocyte differentiation is called “primary ossification center” 
or diaphysis. Ossification progress and erosion of diaphyseal cartilage restricts 
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chondrocytes to the distal end of the elements, called epiphyses. At postnatal day 
7 (P7) the chondrocytes from the center of the epiphysis start to become 
hypertrophic, while at the same time so called “cartilage canals” are generated 
(Blumer et al., 2007; Burkus et al., 1993; Doschak et al., 2003; Ganey et al.,1995; 
Rivas and Shapiro., 2002). Formation of the secondary ossification center is 
regulated by mechanisms similar to those that regulate the formation of the 
primary ossification center. Around P14 hypertrophic chondrocytes undergo 
apoptosis, the ColX matrix is resorbed and blood vessels allow the invasion of 
osteoblasts, which deposit a mineralized matrix, generating the secondary 
ossification center. Between the primary and the secondary ossification center a 
cartilaginous zone persists, called epiphyseal plate or growth plate (Fig.1). The 
proliferation and hypertrophic differentiation of the epiphyseal plate is necessary 
for the continuous longitudinal growth of the bones (reviewed in Blumer et al., 
2008). In humans, growth continues until the end of the puberty when the growth 
plate closes and disappears. In mine most growth plates are maintained 
postnatally, but chondrocytes cease to proliferate. 
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Figure 1. Schematic model of the endochondral ossification process. First 
mesenchymal cells condense and differentiate into chondrocytes (grey) forming the 
cartilage anlagen. Perichondral cells (green) surround the cartilage anlagen. In the center 
of the skeletal element the chondrocytes undergo hypertrophy (prehypertrophic 
chondrocytes, red; hypertrophic chondrocytes, blue) and secrete a ColX rich ECM. 
Perichondrial cells adjacent to the hypertrophic zone differentiate into osteoblasts and 
form the bone collar (orange). Terminal hypertrophic chondrocytes (dark blue) at the 
diaphyses undergo apoptosis, which allows the invasion of blood vessels and osteogenic 
cells. Osteoblasts and osteoclasts replace the cartilaginous structure by bone and bone 
matrix (beige). Postnatally secondary ossification centers develop at the epiphyses. 
Chondrocytes turn hypertrophic and cartilage canals are formed by invagination of the 
perichondrium. Blood vessels invade the epiphyses, bringing osteoblasts and osteoclasts, 
and mineralization starts. 
1.2.3 Groove of Ranvier 
Bone growth in length is detrimental to bone stability, but this effect is 
counteracted by concomitant bone growth in width. This is accomplished by the 
perichondrial groove of Ranvier, a morphological structure surrounding the 
periphery of the epiphyseal cartilage. Three different groups of cells can be 
distinguished within the groove. Surrounding the epiphyseal growth-plate region 
and adjacent to the metaphysis, a group of densely packed cells deep in the 
groove can be found the osteoblasts progenitors that will form the bone cortex. 
Towards the center more widely dispersed and relatively undifferentiated 
mesenchymal cells and fibroblasts, some of which are presumably chondroblast 
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precursors, can be found. These probably contribute to appositional 
chondrogenesis and growth in width of the epiphyseal cartilage. Fibroblasts and 
fibrocytes among sheets of highly oriented and organized collagen fibers form a 
fibrous layer that is continuous with the outer fibrous layer of the periosteum and 
perichondrium (Gigante et al., 1996; Karlsson et al., 2009; Shapiro et al, 1977). 
1.2.4 Articular cartilage  
To allow movement of the body, the skeletal elements articulate in a structure 
called “joint”. Joints are subdivided into different types based on their anatomical 
structure, mobility and shape. They are classified in three major groups:  
1. Fibrous (synarthrodial) - immobile joints.  
2. Cartilagenous (synchondroses and sympheses) - partially moveable joints.  
3. Synovial (diarthrosis) - freely moveable joints that are the most common in the 
skeleton.  
Fibrous joints are connected by dense connective tissue, consisting mainly of 
collagen and are further subdivided into three types: sutures, between bones of 
the skull; syndesmosis found between long bones, such as radius and ulna, tibia 
and fibula; gomphosis between the root of a tooth and the sockets. Cartilagineous 
joints are connected entirely by cartilage, fibrocartilage or hyaline, which consists 
of a mixture of white fibrous tissue and cartilagineous tissue, and contains Col1 in 
addition to Col2. They allow more movement between bones than a fibrous joint. 
The synovial joint is a complex structure consisting of several different tissues and 
can be subdivided in three major structures. 
1. The articular capsule is continuous with the periosteum of bone, is highly 
innervated but avascular.  
2. The articular cartilage lines the epiphyses of joint end of bone and provides the 
loading and unloading mechanism to resist load and shock.  
3. The synovial membrane can be found in the inner layer of the fibrous articular 
capsule and covers the lining of the synovial cavity where articular cartilage is 
absent. 
 Ligaments and tendons support and control movement with the aid of muscles. 
These are separated from the bones by a bursa, a small fluid-filled sac lined by 
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synovial membrane. The synovial membrane secretes synovial fluid, which 
smoothes the friction between the two bone ends. In the knee joint the meniscus, 
an additional curved part of cartilage, acts as a cushion and distributes the weight. 
Synovial fluid can be also found in the bursae, providing a cushion between 
bones, tendons and muscles (Cormack, 1987; Dorland´s medical dictionary 31st 
ed.; Gray´s anatomy, 2005; Seibel and Woitge, 1999).  
During embryogenesis the position of future joints is defined at early stages of 
development. In the mouse this happens around E10.5, soon after the 
cartilaginous templates are formed. At first, a yet unidentified inductive signal 
delimits thin areas of higher cell density called interzones, which consists of 
elongated cells (Edwards et al., 1994). Several data support the hypothesis that 
this cell population is prespecified. Removal of the developing skeletal element 
does not disturb the formation of an interzone, and removal of the presumptive 
joint before its morphological appearance leads to the fusion of adjacent elements 
(Holder 1977). Furthermore retroviral overexpression of the signaling factor 
Wnt9a, one of the earliest markers of the interzone, in developing chicken limb 
bud, results in the formation of a non-cartilaginous skeletal structure, which 
resembles the interzone (Hartmann and Tabin, 2001). This early joint is 
maintained by the expression of several genes, especially Wnt9a and Gdf5 (Storm 
and Kingsley 1999), a growth factor belonging to the bone morphogenetic protein 
(BMP) family. Perturbance of any of these growth factors involved in joint 
sustenance results in joint fusion, as joint-forming cell fate is specified but not fixed 
during development (Khan et al., 2007). Joint cavity development (cavitation) 
occurs along planes of the future articular surfaces of synovial joints. A number of 
different markers have been described to be expressed at the time of cavitation. 
One example is hyaluronan (HA) a glycosaminoglycan found in joint fluid, which 
has a key role in resisting compressive forces (Edwards et al., 1994). HA and its 
receptor CD44 are differentially expressed in the interzone and on the articular 
surface (Archer et al., 1994; Craig et al., 1990; Dowthwaite et al., 1998; Edwards 
et al., 1994; Pitsillides et al., 1995) and the interaction between HA and CD44 can 
induce both cell adhesion and cell separation. This mechanism is depending on 
receptor saturation and HA concentration, with increasing HA amounts leading to 
cell separation (Toole 1991).  
Introduction  
12 
 
In contrast to growth plate cartilage, articular cartilage remains unmineralized and 
forms a resilient, low friction surface capable of absorbing shocks due to 
mechanical loading. It consists of an avascular matrix rich in Col2 and Agc1 and 
maintained by few chondrocytes. Articular cartilage can be subdivided into three 
distinct zones based on different characteristics that include cell shape, cell 
morphology and orientation, and pericellular matrix (PM) deposition (Fig. 2) (Youn 
et al., 2006). In the superficial zone (SZ) cells are small and elongated in shape. 
These are oriented parallel relative to the surface, and lack an extensive PM. The 
middle zone (MZ) is characterized by rounded cells that do not exhibit an 
organized orientation relative to the surface. Deep zone (DZ) cells are identified by 
an extensive PM deposition with chondrons in groups of three or more cells 
arranged in columns oriented perpendicular to the surface (Grogan et al., 2009; 
Tyyni and Karlsson 2000; Youn et al., 2006).  
 
Figure 2. Overview of the structure and zonal architecture of articular cartilage. (a) 
Schematic representation of the articular surface. Each zone can be identified on the base 
of several characteristics like cell shape, morphology, orientation, and pericellular matrix 
(PM) deposition. Adapted from Tyyni and Karlsson (2000). Small, flattened cells in the 
superficial zone (SZ) are arranged parallel to the surface (b), and lack an extensive PM. 
The middle zone (MZ) is populated by rounded cells which show no orientation relative to 
the surface (c) They are rich in proteoglycans and show highly-developed PM. Deep zone 
(DZ) cells are organized in clusters of three or more cells arranged in columns that are 
oriented perpendicular to the surface (d). They show an extensive PM deposition and are 
in contact with the calcified zone (e). (Grogan et al., 2009) 
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1.3 Molecular mechanisms underlying endochondral bone 
formation 
The molecular mechanisms which regulate endochondral ossification comprise a 
large number of signaling pathways. Different human genetic disorders 
characterized by abnormalities of the ossification process are linked to functional 
defects in many of these pathways. 
1.3.1 Indian Hedgehog signaling during chondrocyte differentiation 
The secreted growth factor Indian hedgehog (Ihh), one of the key regulators of 
endochondral ossification, is expressed in prehypertrophic and early hypertrophic 
chondrocytes. Ihh regulates the onset of hypertrophic differentiation interacting 
with a second secreted growth factor, Parathyroid hormone (PTH) related protein 
(PTHrP), also known as Pthlh. Ihh signals through its receptor Patched-1 (Ptch1) 
to the distal periarticular chondrocytes to upregulate the expression of PTHrP. 
PTHrP in turn signals back to its receptor, the PTH/PTHrP receptor (PPR), 
expressed in proliferating and prehypertrophic chondrocytes, thereby inhibiting the 
differentiation of proliferating cells into the Ihh expressing prehypertrophic cell type 
(Lanske et al., 1996; Long et al., 2001; St-Jacques et al., 1999). This negative 
feedback loop is responsible for slowing down chondrocyte differentiation and 
maintaining cells in a proliferative state (Fig.3A) (Vortkamp et al., 1996). In 
addition, Ihh has been shown to play a role in chondrocyte proliferation. Ihh-/- mice 
show normal mesenchymal condensation but the cartilage elements remain small. 
In Ihh-/- chondrocytes chondrocyte proliferation is severely decreased (St-Jacques 
et al., 1999). The regulation of chondrocyte proliferation seems to be independent 
of PTHrP regulation. Correspondingly, overexpression of a constitutive active PPR 
in Ihh deficient mice can rescue the onset of hypertrophic differentiation but does 
not increase the proliferation rate (Karp et al., 2000). Therefore Ihh signaling 
seems to have a direct function on the regulation of chondrocyte proliferation. 
Furthermore targeted deletion of Smoothened (Smon/n), which results in ablation of 
all Hh signals results in a strong decrease of chondrocyte proliferation, whereas 
overexpression of Ihh or a constitutive activation of Smo in chondrocytes leads to 
an increased proliferation rate (Long et al., 2001; Minina et al., 2001). 
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Moreover, Ihh deficient mice lack osteoblasts in endochondral bones. Although 
chondrocytes undergo premature differentiation into hypertrophic cells, these are 
not surrounded by a bone collar. As the ossification of intramembranous bones 
occurs normally, Ihh seem to be necessary to provide an inductive signal 
specifically in endochondral bones. Analysis of mice carrying a targeted deletion of 
Smo in the perichondrium supported this idea as Smon/n perichondrial cells did not 
differentiate into osteoblasts, whereas mesenchymal cells outside the deletion 
area formed an abnormal bone collar (Long et al., 2004). 
1.3.2 Fibroblast growth factor signaling during chondrocyte 
differentiation 
Several syndromes affecting the normal development of the skeleton have been 
linked to mutations of the fibroblast growth factor (FGF) signaling. For example 
Achondroplasia (ACH), which is the most common genetic cause of dwarfism in 
human, and Thanatophoric dysplasia (TD), which is less frequent than the first but 
shows a more severe phenotype. Both syndromes arise from mutations, which 
lead to the constitutional activation of FGFR3, one of four transmembrane 
receptors of the FGF family (Adviezer et al., 2003; Bonaventure et al., 2007; 
Dakouane Giudicelli et al., 2007; Lievens and Liboi et al., 2003; Richette et al., 
2007; Zoltan et al., 2000; Vajo et al., 2000). A mouse model for ACH, the human 
mutation of FgfR3 (FGFR3ach), has been generated, which develops a similar 
phenotype as the human patients. Analyses of these mice showed that dwarfism is 
most likely due to a direct effect of FGF signaling on chondrocyte proliferation and 
differentiation (Naski et al., 1996, 1998; Minina et al., 2002). FGF genes are highly 
conserved in the evolutionary scale from nematode to human. They all share a 
core of 120 aminoacids which confer them a common tridimensional structure, 
associated with the ability to bind heparin, heparin sulfate (HS) and 
glycosaminoglycan (GAG). FGFs are secreted in the ECM and bind to HS with 
high affinity, allowing the binding to their tyrosine kinase receptors which in turn 
dimerize on the cell surface (Courmoul and Deng, 2003; Koga et al., 1999; Olsen 
et al., 2003; Ornitz and Itoh, 2001). It has been shown that activation of FGF 
signaling can rescue the phenotype induced by the reduced synthesis of HS. For 
example, fusion of forelimb synovial joint could be rescued by the constitutional 
activation of FGFR3 (Koziel et al., 2004). The role of the FGF signaling pathway is 
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not limited to early ossification stages. Mesenchymal skeletal progenitor cells in 
the groove of Ranvier have been shown to express FgfR3 (Robinson et al., 1999). 
Moreover, analyses of human fetuses affected by ACH or TD confirmed a strong 
influence of the activated signaling pathway downstream of FGFR3 on the 
development of the groove of Ranvier (Cormier et al., 2002). 
1.3.3 Vascularization of the cartilage anlagen 
1.3.3.1 Vascular endothelial growth factor role during ossification 
Vascular endothelial growth factor A (VEGF-A) plays a key role during 
vascularization, being expressed in both cartilage and perichondrium during early 
development. During the early stages of endochondral ossification the cartilage 
template is an avascular structure. By interaction of different signaling pathways it 
develops into a highly vascularized element, the marrow cavity (Karsenty and 
Wagner, 2002). When chondrocytes turn hypertrophic, they start to produce 
angiogenic factors, inducing the first capillary invasion of the cartilage template 
(Colnot and Helms, 2001; Zelzer et al., 2001). The vasculature supplies the 
template with cells belonging to the osteoblast and osteoclast lineage (Zelzer et 
al., 2002; Colnot et al., 2004). Vegf-A inactivation impairs vascular invasion, 
thereby disturbing subsequent steps of endochondral ossification (Colnot et al., 
2004; Fenwick et al., 1997; Gerber et al., 1999; Maes et al., 2002; Zelzer et al., 
2001, 2002). VEGF-A belongs to the family of VEGF related molecules, which in 
mammals consists of VEGF-A to F and placenta growth factor. Human VEGF-A 
can be alternatively spliced into 5 different isoforms of 121, 145, 165, 189 and 206 
amino acids. The respective isoforms are each one amino acid longer than the 
murine counterparts (Houck et al., 1991; Tischer et al., 1991). They have a 
biological role in endothelial cell (EC) proliferation, migration and 
osteoclastogenesis (Cramer, 2004; Houck 1992; Poltorak, 1997; Wise and Yao, 
2003). VEGF-A165 is the most abundant isoform of VEGF-A and transgenic mice 
expressing only the correspondent isoform (VEGF-A164/164) display normal 
vascular development, whereas mice expressing only the VEGF-A120 isoform are 
characterized by a delayed recruitment of EC into the perichondrium and delayed 
blood vessel invasion into the primary ossification center (Maes et al., 2002, 2004; 
Zelzer et al., 2002, 2004). In vitro experiments have shown that chondrocytes 
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cultured under hypoxic conditions are stimulated to produce VEGF-A165 (Pfander 
et al., 2003). Although VEGF-A189 stimulates EC proliferation and migration in vitro 
(Herve et al., 2005), VEGF-A188/188 mice show dwarfism, impaired development of 
endochondral bones and knee joint dysplasia, leading to the conclusion that this 
isoform might not play a key role during embryonic development, especially with 
regard to chondrocytes differentiation (Maes et al., 2004).  
1.3.3.2 VEGF Receptors 
The biological response to VEGF signaling is mediated by at least three receptors 
(VEGFR1/Flt1, VEGFR2/Flk1 and VEGFR3/Flt4). These synergistically interact 
with HS and 2 co-receptors neuropilin (Nrp1 and Nrp2). VEGFR1-3 belong to the 
Platelet derived growth factor receptor subfamily of receptor tyrosine kinases 
(RTKs) (Fig. 4) (Ferrara et al., 2003). VEGFR1 (or fms-like tyrosine kinase 
receptor1 (Flt-1)) is a 180 kDa transmembrane protein. Evidences suggest that it 
might regulate angiogenesis in two ways. It might act as a negative mediator, via 
its ligand binding domain interacting with VEGFR2 (or kinase insert domain-
containing receptor (KDR)/fetal liver kinase 1 (Flk-1)), and as a positive mediator, 
via its tyrosine kinase domain (Gille et al., 2001). Supporting data comes from in 
vitro studies of VEGFR1-/- embryonic stem cells, in which the differentiation into 
EC is increased, but increased VEGFR2 phosphorylation causes these cells to 
assemble into abnormal vascular channels (Fong et al., 1995; Roberts et al., 
2004). Moreover, VEGFR2-induced EC proliferation can be inhibited by VEGFR1 
(Zeng et al., 2001). VEGFR2, is a 230 kDa glycoprotein which has been proposed 
to play a major role in the biological response of ECs to VEGF signaling (Neufeld 
et al., 1999). VEGFR2 is mainly located on the surface of ECs and its 
phosphorylation on several intracellular sites can initiate signaling, leading to EC 
proliferation, migration and angiogenesis in vivo (Hutchings et al., 2003). Deletion 
of VEGFR2 leads to embryonic lethality, due to impaired vasculogenesis and 
hematopoiesis (Shalaby et al., 1995). VEGFR3 (or fms-related tyrosine kinase 
4(flt4)) is mainly expressed by veins and lymphatic vessels (Adams and Alitalo, 
2007) and the expression of soluble VEGFR3 in the skin inhibits fetal 
lymphangiogenesis (Makinen et al., 2001a). Nrp1 and 2 have been identified as 
VEGF co-receptors and belong to the non-tyrosine kinase transmembrane 
receptors, with a small cytoplasmatic domain and multiple extracellular domains 
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(Soker, 1998). Although they lack an intracellular signal transduction domain, Nrp1 
and 2 have an active role as mediator in immune response, neuronal development 
and angiogenesis (Klagsbrun et al., 2002). Nrp1 is involved in angiogenesis and in 
bone formation. It has a high affinity for VEGFR2 (Shraga-Heled et al., 2007) and 
induces the formation of extra-digits when overexpressed (Kitsukawa et al., 1997). 
NRP2 acts mainly on lymphangiogenesis (Yuan et al., 2002).  
 
Figure 4. Schematic representation of the VEGF receptors and their ligands. The 
tyrosine kinase receptors (VEGFR-1/Flt-1, VEGFR-2/KDR/Flk-1, VEGFR-3/Flt-4) have 7 
extracellular immunoglobulin (Ig)-like domains. The second and third Ig-like domains bind 
to VEGF. The fourth Ig-like domains interact directly with each other in a ligand-induced 
receptor dimerization. The extracellular domain is followed by a single transmembrane 
region and an intracellular tyrosine-kinase domain. Interactions of VEGFRs with either 
Nrps or HS (HSPG) facilitate the binding of VEGF to its receptor. Preferential ligand-
receptor bindings are indicated (Dai and Rabie, 2007).  
1.4 Heparan sulfate role during endochondral ossification 
1.4.1 Heparan sulfate biosynthesis 
Heparan sulfate proteoglycans (HSPGs) are a major component of the 
extracellular matrices. HSPGs are large macromolecules composed of heparan 
sulfate glycosaminoglycan (HS-GAG) chains. These are linear polysaccharides 
composed of alternating sugar residues of D-glucuronic acid (GlcA) and N-acetyl-
D-glucosamine (GlcNAc), linked to a protein core (Zhang and Esko, 1994). Core 
proteins are subdivided into extracellular matrix core proteins like Agc1 and 
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perlecan (Hspg2), and membrane-associated core proteins such as syndecans 
(Sdc1–4), glypicans (Gpc1–6), and CD44. HS biosynthesis is a complex process 
involving, among others, multiple glycosyltransferases, sulfotransferases and an 
epimerase. Together, they are responsible for the elongation and modifications of 
the GAG chains (Fig. 5). The first step of HS biosynthesis is the transfer of xylose 
from UDP-xylose by xylosyltransferase to specific serine residues within the PG 
core polypeptide. Galactosyltransferases I and II attach two galactose (Gal) 
residues and glucuronosyltransferase I completes the formation of a core protein 
linker tetrasaccharide by adding a GlcA residue. This linker sequence is common 
to chondroitin sulfates (CS) and HS. In the next step, exostosin like 2 (EXTL2) 
defines the polymerization of HS rather than CS by adding a single GlcNAc 
residue (Kitagawa et al., 1999). Upon this the glycosyltransferases complex 
consisting of Exostosin1/2 (EXT1/2) catalyzes the addition of alternating units of 
GlcA and GlcNAc residues (Lind et al., 1998; McCormick et al., 1998). Subsequent 
to the polymerization of the GAG chains, the individual sugar residues undergo 
further modification, that include GlcNAc N-deacetylation and N-sulfation (Ndst1–
4), C5 epimerization of GlcA to iduronic acid (Glce), O-sulfation at C2 of iduronic 
acid and GlcA (Hs2st), and O-sulfation at C6 of GlcNAc and GlcNS (Hs6st1–3). 
These modifications generate tissue specific patterns of differentially sulfated 
motives, resulting in the formation of specific growth factor binding sites. (Bernfield 
et al., 1999; Esko and Lindahl, 2001; Lander and Selleck, 2000; Lindahl et al., 
1998). 
HS binds to a variety of protein ligands, as growth factors, extracellular enzymes 
and cytokines and regulates a wide range of biological activities, including 
development, angiogenesis, blood coagulation and tumor metastasis (Esko and 
Selleck, 2002). HS also binds with high affinity to FGF and is required for the 
diffusion of several morphogens, including Ihh, Bone morphogenetic proteins 
(BMPs) and Wnt. 
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Figure. 5. Schematic representation of heparan sulfate synthesis and modification. 
GAG side chains are attached to specific serine residues of core proteins. GAG synthesis 
is initiated by the addition of a common tetrasaccharide linker (-Xyl-Gal-Gal-IdoA-). HS 
synthesis starts by adding N-acetyl-D-glucosamine (GlcNAc) to the linker by Extl2. The 
HS chain is elongated by alternate addition of glucuronic acid (GlcA) and GlcNAc by the 
EXT1/2 complex. The nascent HS chains undergo modifications including N-
deacetylation/N-sulfation, epimerization, and O-sulfation (6-O; 3-O and 2-O sulfation), 
generating tissue specific patterns of differentially sulfated motives. (NS, C2-N-sulfation; 
2S, C2-O-sulfation; 6S, C6-O-sulfation). (Esko and Selleck, 2002) 
Introduction  
20 
 
1.4.2 Multiple Osteochondromas syndrome 
Multiple osteochondromas (MO) syndrome is an autosomal dominant disease 
characterized by the formation of benign bone tumors at the distal ends of long 
bones, which are also known as exostoses (Ahn et al., 1995; Stickens et al., 
1996). Osteochondromas develop and increase in size during childhood and 
cease to grow when the growth plate closes at puberty. Morphologically, they 
consist of a bony stalk which is in contact with the cortical bone and the bone 
marrow and is flanked by a cartilage cap at the distal end (Fig. 6B). Histological 
analyses revealed that chondrocytes from the cartilage cap show a similar cellular 
organization as the growth plate. Most osteochondromas develop predominantly 
around the knee and vary widely in size. Osteochondromas can be peduncolate or 
sessile, with a broad base (Hennekam, 1991). Complications of the syndrome 
include osseous deformities, bursa formation and arthritis. Furthermore, 
impingements on adjacent tendons, nerves, vessels or the spinal cord have been 
observed (Vanhoenacker, 2001; Wicklung et al., 1995). In up to 5% of human 
patients osteochondromas can transform into malignant osteochondrosarcomas 
(Gordon et al., 1981; Legeai-Mallet et al., 1997; Peterson, 1989; Schmale et al., 
1994; Wicklund et al., 1995;). Furthermore MO syndrome has been linked to 
mutations in two main loci, EXT1 on chromosome 8q24.1 (Ahn et al., 1995; 
Lüdecke et al., 1997) and EXT2 on chromosome 11p11-p12 (Bovée et al., 1999; 
Wuyts et al., 1998, Wuyts and Van Hul, 2000).  
The severity of the MO phenotype is defined by the degree of stature shortening, 
the number of tumors and the severity of skeletal deformities. A genetic screen 
revealed that mutation in either EXT1 or EXT2 could be identified equally and 
occurred in 83% of the human patients. Interestingly, the more severe phenotypes 
have been correlated to mutation in EXT1 rather than EXT2 (Fig.6A) (Porter et al., 
2004). Human EXT1 and EXT2 are ubiquitously expressed proteins of 746 and 
718 amino acids, respectively. They are highly conserved displaying a 70% 
homology on protein level (Ahn et al., 1995; Wuyts et al., 1996). Both proteins are 
glycosyltransferases with a predicted type II transmembrane glycoprotein structure 
(Lind et al., 1998; McCormick et al., 1998). In vitro studies have shown that EXT1 
and EXT2 co-localize at the Golgi membrane, forming a heterodimeric complex, 
which promotes the elongation of HS chains (McCormick et al., 2000). Mutations 
in both genes are occurring mainly in evolutionarily highly conserved residues that 
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are crucial for the activity of the protein. Approximately 80% of the mutations are 
either nonsense, frameshift, or splice site mutations leading to premature 
termination of EXT proteins (Francannet et al., 2001; Park et al., 1999; Raskind et 
al., 1998; Seki et al., 2001; Wuyts et al., 1998; Xu et al., 1999;). The majority of 
missense mutations also lead to defective EXT function (Cheung et al., 2001) 
(Fig.6C).  
Osteochondromas have for a long time been considered the consequence of 
skeletal dysplasia. It is now generally accepted that exostoses are neoplastic, as 
somatic mutations have been found within the cartilage cap. As mutations are 
autosomally dominant inherited, the EXT genes has been considered as a tumor 
suppressor gene. Correspondely loss of heterozigosity has been demonstrated in 
the cartilage cap of osteochondromas from MO patients (Bovée et al, 1999, 
Hameetman et al., 2007). However, this second mutation could not be detected in 
all MO patients, raising the question for the initial event in the development of the 
disease. 
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Figure 6. Human phenotype of osteochondromas syndrome. (A) Percentage and 
distribution of palpable osteochondromas found in a study conducted by Porter and 
colleagues on 172 individuals affected from MO (Porter et al., 2004). (B) X-ray analysis of 
a knee joint from a 15 years old patient affected by MO. Osteochondromas (indicated as 
“extra bone”) develop as bony projections at the epiphyseal side of tibia and femur. (John 
Csongradi, National health museum). (C) Immunostaining with a Perlecan antibody. 
Strong staining is detected around control chondrocyte lacunae and minimal staining 
around the plasma membrane and the pericellular matrix (C: a). Staining in 
osteochondromas has no consistent pattern and the lacunae are not heavily stained (C: b-
e)(Hecht et al., 2002, modified). 
1.4.3 Ext genes in endochondral ossification and osteochondromas 
mouse models 
In situ hybridization of Ext1 and Ext2 showed that both genes are strongly 
expressed in the developing mouse limb bud, with expression confined to the 
regions of proliferating and prehypertrophic chondrocytes in the growth plate 
(Stickens et al., 2000). In human osteochondromas EXT gene expression is 
reduced corresponding to their mutational status. As a consequence, HS seems to 
accumulate in the cytoplasm of the cell, instead of being transported to the cell 
!
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surface (Hameetman et al., 2007). In the attempt to study the role of EXT proteins 
in vivo, different mouse models have been generated. Homozygous Ext1-/- and 
Ext2-/- mice cannot synthesize HS and die around E9, before gastrulation is 
completed (Stickens et al., 2005; Lin et al., 2000). Ext1Gt mice carry an insertion of 
a gene trap vector in the first intron of Ext1 that leads to the generation of a non-
functional truncated protein. Ext1Gt/Gt mutant survive until E16.5 (Koziel et al., 
2004; Lin et al., 2000). In contrast to human MO patients, heterozygous Ext1+/-, 
Ext1+/gt or Ext2+/- mutants do not develop exostoses at the appendicular skeleton. 
However Ext2+/- mice develop small exostoses at the costochondral cartilage of 
the ribs with low frequency (28%) (Stickens et al., 2005). Recent analyses of 
Ext1Gt/Gt mice helped to elucidate how the Ihh signal reaches the joint region to 
induce the expression of PTHrP. Initially, secondary factors have been 
hypothesized to mediate the Ihh signal. The phenotype of Ext1Gt/Gt mice strongly 
support a model in which heparan sulfate (HS) negatively regulates the 
propagation of Ihh in the cartilage anlagen, acting Ihh as a long range morphogen 
directly inducing the expression of PTHrP. Early stages of chondrocytes 
differentiation are perturbed in Ext1Gt/Gt mice, due to disturbed Ihh signaling. 
(Fig.3B)(Koziel et al., 2004).  
 
Figure 3. Ext1-Dependent HS regulates Ihh signaling. (A) Ihh, expressed in 
prehypertrophic chondrocytes (red), travels through the cartilage anlagen to directly 
activate the expression of PTHrP (Pthlh, yellow). Ihh signaling induces strong Ptch1 
expression (dark blue) in columnar chondrocytes flanking the Ihh expression domain and 
weaker Ptch1 expression in distal chondrocytes including the periarticular, PTHrP-
expressing cells (light blue and yellow) (Vortkamp et al., 1996). HS (brown) negatively 
regulates the propagation of the Ihh signal. (B) Reduced amount of HS in Ext1Gt/Gt mutants 
facilitates Ihh diffusion and leads to an increased domain of strong Ptch1 expression and 
Introduction  
24 
 
upregulation of PTHrP. PTHrP in turn delays the onset of hypertrophic differentiation 
(Koziel et al., 2004). 
The cellular origin of osteochondromas has not been identified yet and different 
cell types have been discussed. In human patients, homozygous loss of EXT 
function has been identified within the cartilage cap, suggesting a chondrogenic 
origin (Hameetman et al., 2007). Alternatively previous experiments have shown 
that an injury at the site of the perichondrium leads to the formation of solitary 
osteochondromas-like structures, pointing to a perichondrial cell as the origin of 
exostoses (Delgado et al., 1987). As a rival model the perichondrial groove of 
Ranvier acts as a reservoir for chondrocyte and osteoblast progenitors and cells 
from this structure have been discussed as candidate for the origin of cartilage 
tumors (Cormier et al., 2002; Gigante et al., 1996; Robinson et al., 1999, 2001) 
1.4.4 Arthritis 
About 14% of human patients affected by MO develop arthritis (Wicklung et al, 
1995), which is the primary cause of degenerative joint diseases. It is 
characterized by breakdown and eventual loss of the cartilage at the articular 
surface due to trauma, infection or biochemical defects. The two most common 
types of arthritis are Osteoarthritis (OA) and Rheumatoid arthritis (RA). OA is 
caused by the breakdown of joint cartilage, which causes bone ends to grind 
against each other. Usually, OA affects a single joint. RA on the other hand, is a 
chronic, inflammatory type of arthritis, which affects multiple joints. It is also 
classified as an autoimmune disease, as immune cells attack the body's own 
healthy tissues (Roche Lexicon Medicine, 1987). The synovium is primarily 
affected by RA, but other organs can be affected as well (Hunziker, 2002; 
Solchaga 2001). OA is the most common human joint disorder, highly reducing 
quality of life and impairing movement by acute and chronic pain (Koopman, 1997; 
Resnick, 2002). Degradation of the cartilage matrix is associated with increased 
proteolysis of proteoglycan and collagen. A typical symptom of OA is the 
increased expression and synthesis of matrix degrading enzymes, like Mmps and 
aggrecanases, in synovial tissue and cartilage (Lark et al., 1997; van Lent et al., 
2005; Valverde-Franco et al., 2006). This leads to the degradation of Agc1 of the 
articular cartilage into specific catabolic fragments, which accumulate in the 
extracellular matrix. These fragments can be detected by antibodies against 
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degradation specific epitopes, known as VDIPEN and NITEGE, referring to the 
amino acid sequence produced by Mmp or aggrecanase cleavage. 
Agc1 degradation has been intensely studied during the past few years (Fosang et 
al., 1995; Lark et al., 1997; Mercuri et al., 1999; Valverde-Franco et al., 2006; 
Westling et al., 2002). Several transgenic models have been used to identify 
possible predisposition causes and to understand the mechanisms underlying the 
development of OA. An increase in ColX expression, apoptosis of chondrocytes, 
large lacunae and faint staining for proteoglycans are common symptoms of OA 
(Pirog-Garcia et al., 2007; Valverde-Franco et al., 2006; van Lent et al., 2005).  
 
Figure 7. Healthy and arthritic joints. A normal, healthy joint allows movement by 
smooth sliding of the two articular surfaces, lubricated by a synovial fluid. Arthritis modifies 
the articular surface of bones. In Osteoarthritis loss of cartilage brings the two bone ends 
to rub against each other, causing friction. In Rheumatoid arthritis, chronic inflammation 
as consequence of autoimmunoresponse leads to the destruction of cartilage, bone, and 
ligaments, causing deformity of the joints (Medicinenet.com, retrieved on 11th November, 
2009). 
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2. Aim of the study 
‘Multiple Osteochondromas’ (MO) is an autosomal dominant inherited human 
disorder characterized by short stature and cartilaginous-capped benign bone 
tumors, also known as exostoses. These develop in juxta-epiphyseal position of 
the growth plate of actively growing bones and remain connected to the bony shaft 
( Bovée et al., 2008). In most MO patients (>90%) heterozygous mutations in the 
genes, Exostosin1 (EXT1) and EXT2, respectively, have been identified (Ahn et 
al., 1995; Stickens et al., 1996). Homozygous deletion of Ext1 or Ext2 in mice 
results in lack of HS biosynthesis. These mice die at E9.5 due to defects in 
mesoderm formation. In contrast to human MO patients, heterozygous Ext1+/- or 
Ext2+/- mutants do not develop exostoses in the appendicular skeleton.  
The cellular origin and the molecular mechanism inducing osteochondroma 
development have been controversially discussed for many years and different 
studies came to different conclusions (Bovée et al., 1999; Hall et al., 2002).  
In this study, two different transgenic mouse models will be analyzed to identify the 
origin of osteochondroma, Ext1Gt/+ mice carrying a hypomorphic Ext1 allele and 
produce reduced amounts of heparan sulfates. Homozygous mice survive until 
E16.5 (Yamada et al., 2004). Early stages of chondrocytes differentiation are 
disturbed in Ext1Gt/Gt mice, as Ihh protein traveling along the cartilage anlagen is 
facilitated by reduced amount of HS (Koziel et al., 2004). In addition to regulating 
chondrocyte differentiation, Ihh signaling also regulates osteoblast differentiation 
and vascularization of the cartilage elements (Joeng and Long, 2009; Kinto et al., 
1997). Therefore, the effect of HS on the differentiation of osteoblasts and 
osteoclasts should be investigated in Ext1Gt/Gt mutants. As vascularization is an 
important step during endochondral ossification, the distribution of blood vessels 
and the migration of endothelial cells will be analyzed in the Ext1Gt/Gt mutants.  
As mentioned previously, Ext1-/- mice die prior to bone formation and Ext1Gt/+ mice 
do not develop exostoses. To investigate the molecular origin of 
osteochondromas, we used a mouse line carrying a conditional deletion of Ext1 
allele (Ext1e2fl). Homozygous Ext1e2fl/e2fl mutants were crossed to mice carrying a 
Cre recombinase allele, which is expressed under the control of a doxycycline 
inducible Col2 promoter (Col2-rtTA-Cre) (Grover and Roughley, 2006). To clarify if 
loss of heterozygosity or haploinsufficiency leads to osteochondromas 
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development small clones of cells will be isolated by laser microdissection and 
genetically analyzed for their allelic status and HS content to understand the role 
of HS during osteochondromas development.  
Material and Methods 
28 
 
3. Material and methods  
3.1 Material 
3.1.1 Chemicals 
All chemicals, if not noted otherwise, were purchased from the companies Merck, 
Sigma or Roth. 
- Acetic anhydride (Sigma) 
- Agar (Difco) 
- Agarose (Gibco BRL) 
- Betaine (N,N,N –trimethylglycine) (Sigma) 
- Chondroitinase ABC (Sigma) 
- CTP, GTP, ATP, UTP (Roche) 
- Dextran Sulfate (Sigma) 
- DNAse (deoxyribonuclease), RNAse free (Roche) 
- dNTPs (2'-Deoxynucleoside 5'-triphosphates) (Roche) 
- Dream Taq-Polymerase (Fermentas (St. Leon-Rot)) 
- DPX Mountant for histology (Fluka) 
- Ethidiumbromide (Serva, Heidelberg) 
- Ficoll 400 (Pharmacia) 
- Glass coverslips (Menzel-Glaeser, Germany) 
- Glutaraldehyde (Sigma) 
- Glycogen (Roche) 
- Hyaluronidase I form bovine testis (Sigma) 
- Kaisers Gelatine (Merck) 
- Paraffin-paraplasts (Sherwood Medical Co, USA) 
- PEG 4000: polyethylenglycol (MBI Fermentas) 
- PFA (Paraformaldehyde) (Merck) 
- Proteinase K (Roche) 
- [P33]-UTP (radioactive Uridintriphosphat) (Hartmann Analytik (Braunschweig)) 
- Random primer: pd(N)6 Random Hexamer 5’-Phosphate (Invitrogen) 
- Restriction endonucleases (NEB, Roche) 
- Ribonuclease A, RNAse A (Roche) 
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- RNAse inhibitor (Roche) 
- Superfrost plus slides (Menzel-Glaeser, Germany) 
- Taq-DNA polymerase (Eppendorf) 
- TEA, triethanolamine (Merck) 
- Tissue culture dish 60x15 mm (Falcon) 
- Toluidine Blue O (Sigma) 
- Tryptone (Difco) 
- T7, T3, SP6 RNA-polymerase (Roche) 
- T4 DNA Ligase 400U/µl (New England Biolabs) 
- (3-aminopropyl)triethoxysilane (Sigma) 
3.1.2 Technical equipment 
Technical equipment  Manufacturer 
- 20°C-freezer Liebherr, Bosch 
- 80°C-freezer (HERAfreeze) Thermo 
-152°C Sanyo 
Agitator VWR, Heidolph 
Automatic tissue processor Mikrom 
Laboratory scales Mettler Toledo 
Bacteria agitator Infors 
Bacteria incubator Memmert 
Bench centrifuge Eppendorf, Hettich 
Beta/gamma (Geiger) counter (COMO) S.E.A. 
Camera for microscope Visitron Systems 
Cell culture microscope Leica 
Cryostat Mikrom 
Developing machine for film (Curix 60) AGFA, Leverkusen 
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Electrophoresis chamber Angewandte Gentechnologie Systeme 
Embedding station Leica 
Gel imager  INTAS 
Heat block Eppendorf, HLC 
Hotplate for sections MEDAX 
Hybridization oven Unitherm 
Incubator Labotect 
Luminometer (Centro LB 960) Berthold Technologies 
Magnetic stirrer Heidolph 
Microscope Leica 
Microtome Mikrom 
Microwave Sharp 
pH-Meter Hanna Instruments 
Nanodrop Peqlab 
Pipet-Boy MATRIX 
Pipettes Eppendorf, 
Powersupply Biometra 
Refrigerators Bosch 
Steril hood (HERA safe, MSC-Advantafe) Thermo, BDK 
Stereomicroscope Zeiss 
Thermocycler Eppendorf, Biometra, Göttingen 
Vortex shaker Scientific Industries 
Water system (Milli-Q System) Millipore, Schwalbach 
Water bath GFL, Thermo 
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Waterbath for sections MEDAX 
Cell culture consumables were purchased from Corning and Falcon. 
3.1.3 Software 
CLC-bio Version 4.01 
INTAS GDS  
Microsoft Office2007 12.0 
MicroWin 2000, Version 4.41 
Spot Advanced Version 4.5.7 
3.1.4 Buffers and Solutions 
- 0.001% Fast Green (FCF) Solution: 0.01 g Fast green, 1000 ml Distilled water  
- 0.1% Safranin O Solution: 0.1 g Safranin O, 100 ml Distilled water  
- 0.1M Sodium Acetate Buffer, pH4.2: 1.36 g Sodium acetate, trihydrate, 100 ml 
Distilled water. Mix to dissolve and adjust pH to 4.2 using concentrated glacial 
acetic acid  
- 1% Acetic Acid Solution: 1 ml Acetic acid, glacial, 99 ml Distilled water   
- 1% Aqueous Silver Nitrate Solution: 1 g Silver nitrate, 100 ml Distilled water    
- 5% Sodium Thiosulfate:  5 g Sodium thiosulfate, 100 ml Distilled water     
- 25% EDTA: 250gr Triplex III, 60ml 10M NaOH, 1 liter distilled water, to pH7.4 
- Alcian blue staining solution (Skeletal staining): 15 mg Alcian blue 8 GX (Sigma), 
80 ml 95% Ethanol, 20 ml Glacial acetic acid 
- Alizarin red staining solution (Skeletal staining): 50 mg Alizarin Red (Sigma), 1 
liter 1% KOH 
- Alcian blue solution (Micromasses): 0.05% Alcian blue 8 GX (Sigma), in 75% 
EtOH: 0.1M HCl (4:1) 
- Collagenase digestion solution: 0.3 U/ml Collagenase NB4 (Serva) in sterile 
1XPBS containing 5% FCS and 0.05% Trypsin-EDTA (Invitrogen). 
- Endothelial cell medium: Endothelial basal medium MCDB 131 (PAA U15-011) 
was supplemented with 20%FCS (Invitrogen-Gibco), 50U/ml Penicillin/50µg/ml 
Streptomycin (Invitrogen-Gibco), 10µg/ml Hydrocortisone (Sigma, water soluble H-
0396), 80µg/ml endothelial cell growth supplement (ECGS from bovine pituitary 
Sigma E0760).  
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- Gel-loading-buffer (10x): 15% Ficoll (Type 400); 0,25% Bromphenolblue; 6 mM 
EDTA,pH 8.0 
- Hybridization buffer: 50% Formamid; 3 M NaCl; 20 mM Tris-HCl; pH 7.4; 5 mM 
EDTA; 
- Kodak-developer D-19 (Kodak, USA) 
- Kodak-fixer (Kodak, USA) 
- Kodak Scientific Imaging Film (Kodak, USA) 
- LB medium (Luria Bertrani): 1% tryptone; 0,5% yeast extract; 1% NaCl, pH 7.0 
- LB agar: 15g agar per 1L LB-medium 
- Methyl Green Solution (0.5%): 0.5 g Methyl green (ethyl violet free from Sigma), 
100 ml 0.1M Sodium acetate buffer, pH4.2  
- MACS Cell isolation buffer: 1xPBS supplemented with 0.5% BSA and 2mM 
EDTA 
- Micromass culture medium: DMEM/F12 (Invitrogen (Gibco)) supplemented with 
10%FCS and 50U/mlPenicillin/50µg/mlstreptomycin  
- Paraformaldehyde 4% (w/v) in PBS 
- PBS (Phosphat Buffered Saline): 1.5 mM KH2PO4; 140 mM NaCl; 3 mM KCl; pH 
7.4 
- Photoemulsion (autoradiography emulsion type NTB2) (Kodak, USA) 
- Proteinase K: 10mg/ml resuspended in 50 mM Tris-HCl, pH 8,0; 1 mM CaCl2, 
- RNAse free water (DEPC water) 0.1% DEPC (Diethylpyrocarbonat) 
- Scott’s buffer (10g MgSO4, 2g Natriumbicarbonate in 1000 ml H2O) 
- SOC medium: 2% tryptone; 0.5% yeast extract; 10 mM NaCl, 2.5 mM KCl, 10 
mM 
MgCl2 and 20 mM glucose 
- SSC (standard saline citrate, 20x): 300 mM Sodium citrate; 3 M NaCl; pH 7.0 
- TAE-buffer (50x): 2 M Tris, pH 7,5 - 8,0; 50 mM EDTA 
- Transcription buffer (10x): 0.4M Tris-HCl, pH 8,0; 60 mM MgCl2; 100 mM 
dithiothreitol,  
- Toluidine Blue: 1 g Toluidine Blue O, 2 g Sodium Borate (Borax), 100 ml Distilled 
Water  
20 mM spermidine (Roche) 
- Washing buffer (10x): 4 M NaCl; 0.1M Tris-HCl; 0,05 M EDTA; pH 7.5 
- Weigert's Iron Hematoxylin Solution: Mix equal parts of stock solution A and B 
(ready to use).  
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- Y-Eosin: 100ml Eosin; 0.5ml Glacial acetic acid 
3.1.5 Kits 
- DAB-staining kit (Pierce)  
- EVA Green PCR Master Mix (Bio Budget) 
- Nucleospin-RNA isolation (Macherey Nagel) 
- Plasmid Midiprep kit (Qiagen) 
- qRT-PCR-Kit: Superscript III (Invitrogen) 
3.1.6 Protein names and their synonyms 
PTHLH, parathyroid hormone-like hormone: PTH-like; parathyroid hormone 
related protein (PthrP); parathyroid hormone-related peptide; PTH-related peptide 
PTHR1, parathyroid hormone receptor: PPR/PTH-related peptide receptor; 
PTH/PTHrPR 
BGLAP1, bone Gla protein: Osteocalcin mOC-A/ OG1 
VEGF: vascular endothelial growth factor: VEGF-A splice variant A 
VEGFR1, VEGF receptor 1: Flt1, fms-like tyrosine kinase receptor1 
VEGFR2, VEGF receptor 2: KDR, kinase insert domain-containing receptor, Flk-
1, fetal liver kinase 1 
NRP1, neuropilin 1 
3.1.7 Bacterial strain 
Escherichia coli DH5aTM. Genotype : F-f80dlacZDM15 D(lacZYAargF)U169 deoR 
recA1 endA1 hsdR17(rk-, mk +) phoA supE44 1-thi-1 gyrA96 relA1(Gibco BRL, 
Karlsruhe). 
3.1.8 Mouse lines 
Ext1Gt/Gt mice (official designation, Ext1Gt(pGT2TMpfs) 064Wcs) were provided by 
Olivia G. Kelly and William C. Skarnes (Mitchell et al., 2001). Ext1e2neofl/ e2neofl 
(official designation, Ext1tm1.1Kjns) were provided by Kevin B. Jones (Jones et al., 
2010). 
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3.1.9 Mouse and rat DNA probes for in situ transcription 
Probe, Vector, Insert size (basepairs: bp), DNA Endonuclease (for antisense), 
RNA polymerase (for antisense), Reference 
rCol2, pGEM-3Z, 550 bp, Hind III, T7, (Kohno et al., 1984) 
mCol X, pBSK+, 400 bp, Cla I, T3, (Jacenko et al., 1993) 
Mmp13, pCR-TOPO21, 1000 bp, Hind III, T7, (Yamagiwa et al., 1999) 
Bglap1, pBSK, 500 bp, Xba I, T3, (Celeste et al., 1986) 
mIhh, pBSK, 1800 bp, Xba I, T7, (Bitgood and McMahon, 1995) 
mPtch1, pBSK, 5000 bp, BglII, T7, (Goodrich et al., 1996) 
Ucma pBSK, 417 bp, Not I T3, (Tagariello et al., 2008) 
Vegf-A pCR-TOPO21, 300 bp, Hind III, T7 (Stricker et al., 2002) 
Flt-1 pBSK+, 1.6Kb, BAM HI, T7 (Finnerty, 1993) 
Flk-1 pBSK+, 1 KB, BAM HI, T7 (Quinn, 1993) 
Nrp1 pCR-TOPO21, 831 bp, Hind III, T7 (was a kind gift of Dr. Elazar Zelzer) 
3.2 METHODS 
3.2.1 Doxycycline administration 
Expression of Cre-recombinase in Col2-rtTA-Cre mice was induced either by 
administration of 4 mg/ml doxycycline in 5% sucrose through the drinking water of 
the lactating mother at P8 for 8 days or by intraperitoneal injection of doxycycline 
(80 µg/gram body mass) in 1xPBS into lactating mothers at P8. 
3.2.2 Quick preparation of genomic DNA for mouse genotyping 
Small pieces of mouse tails were incubated in 200 µl Viagen direct PCR-Tail 
(PeqLab Biotechnology GmbH) with 0.2 mg/ml Proteinase K at 55 °C overnight. 
After inactivation at 85°C for 45 minutes, PCR was performed directly on lysate. 
3.2.3 PCR-Methods 
The polymerase chain reaction method allows the amplification of DNA fragments 
with specific oligonucleotide primers The PCR products can be fragmented by gel 
electrophoresis, purified and used for cloning (Mullis et al., 1986; Saiki et al., 
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1985). For a standard PCR reaction the reaction mixture consisted of the following 
components: 10 ng of plasmid or 100 ng of genomic DNA; 2,5 µl 10x PCR-buffer; 
0,25 µl 25 mM dNTPs, 1,25 µl of each primer (10µM) and 0,5 µl of 5U/µl Taq-
polymerase. Amplification conditions were: 94°C for 5 minutes; 30 cycles of 94°C 
for 30 seconds, an appropriate annealing temperature for 30 seconds, 68°C for 1 
minute and 72°C for 7 minutes. The PCR-products were analyzed in a 1% agarose 
gel. 
3.2.3.1 Genotyping of mice by PCR 
For genotyping of mice the standard PCR protocol was used, if not otherwise 
indicated. 
Primers for Ext1Gt/Gt mice (ascertained by inverse PCR): 
Ext1fw: 5’-CACATCAGGTGCCTCACAAC-3’ 
Ext1rv: 5’-CTCCCAGCACTTTTCCTGAC-3’ 
5’pgto: 5’-TACATAGTTGGCAGTGTTTGGG-3’ 
PCR conditions for genotyping of Ext1Gt/Gt mice were: 94°C for 5 minutes; 30 
cycles 
of 94°C for 45 seconds, 60°C for 45 seconds, 72°C for 1 minute; and 72°C for 7 
minutes. 
The resulting 800 bp fragment indicated the transgenic allele and a 600 bp 
fragment indicates the wild-type allele. 
For Ext1e2neofl allele routine genotyping was done with a panel of primers used to 
detect recombination as indicated in Fig. 8. In addition, presence or absence of 
Cre-recombinase was confirmed by PCR in each mouse. 
 
 
Figure 8. Genotyping primers for Ext1e2neofl mice 
Ext1 recombination genotyping 
Primer A: GAGTCCATCCTGCTCTGCAT 
Primer B: TTGTTGCATGGGAAAGACAA 
Primer C: CCAAACTGGTTTCAAGCTTT 
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Primer D: CGTTGGCTACCCGTGATATT 
Primer E: CTCCCAATTCTGGCTCTTCA 
Cre-recombinase genotyping 
Forward: ACCAGCCAGCTATCAACTCG 
Reverse: TTACATTGGTCCAGCCACC 
3.2.3.2 Nested PCR 
First round of nested PCR was performed in single reaction with three primers (A, 
B and C Outer) with an annealing temperature of 58°C. Second round of nested 
PCR was performed with two separated reactions (primers A and B inner and A 
and C inner) with an annealing temperature of 62°C. 
 
Laser-capture microdissection clone genotyping 
A-Outer: ACCAGCTACAGATCAACA (both alleles) 
B-Outer: CTCACCTTCCCATTTAGT (Ext1e2fl) 
C-Outer: AGGCTTAGTTATTTGGGG (Ext1e2flinv) 
A-Inner: ACCCCTCCCCCACCTGATTTA (both alleles) 
B-Inner: GCGCACGCCTTTAATCCCA (Ext1e2fl) 
C-Inner: ACTTTCTGTCTGGTTCCTCGT (Ext1e2flinv) 
3.2.3.3 RNA isolation and cDNA synthesis 
The reverse transcription polymerase chain reaction is the most sensitive method 
for the detection of low-abundance mRNA. Total RNA was isolated from 
micromasses of Ext1Gt/Gt, Ext1Gt/+ and wild-type embryos with Nucleospin kit 
(Macherey-Nagel) following manufacturer instructions. The quantity and quality of 
the isolated total RNA was determined by photometric measurement. 
The cDNA was generated by reverse transcription with Superscript III kit 
(Invitrogen) using random primers.  
3.2.3.4 Quantitative Real time PCR 
Direct detection of the PCR product can be monitored by measuring the increase 
in fluorescence caused by the binding of SYBR Green dye to double stranded 
DNA. For PCR the following primers were used: 
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mCol2-Fw: 5´- CGAGTGGAAGAGCGGAGACT -3´ 
mCol2-Rv: 5´- AACTTTCATGGCGTCCAAGGT -3´ 
mColX-Fw: 5´- ACGGCACGCCTACGATGT -3´ 
mColX-Rv: 5´-CCATGATTGCACTCCCTGAA -3´ 
mVEGF-A-Fw: 5´- GCTGTGCAGGCTGCTGTAAC -3´ 
mVEGF-A-Rv: 5´- CCTATGTGCTGGCTTTGGTG -3´ 
mBglap-Fw: 5´- ACCCTGGCTGCGCTCTGTCTCT -3´ 
mBglap-Rv: 5´-GAT GCGTTTGTAGGCGGTCTTCA -3´ 
cDNAs were normalized against transcript levels of ß2Microglobulin : 
mß2M-Fw: 5’- GCTCGGTGACCCTGGTCTTT -3’ and 
mß2M-Rv 5’- GAGGCGGGTGGAACTGTGTT-3’ 
One PCR reaction mixture consisted of: 10 µl cDNA (diluted 1/10 V), 5 µl primer 
(final concentration 7.5 pM in 5 µl) and 15 µl SYBR Green Master Mix. PCR 
conditions were: 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 
seconds and 60°C for 1 minute. After the last PCR cycle the melting curves for the 
amplification products were measured from 60°C to 95°C. The results were 
analyzed with the SDS software (Applied Biosystems). The quantification of the 
PCR product is based on the calculation of the fluorescence threshold value (CT-
value). The CT-value is that PCR-cycle in which the reporter-fluorescence 
exceeds the background-fluorescence. After the CT-value is reached the kinetics 
of the amplification reaction should be exponential. The CT-values of different 
templates can be compared with each other (relative quantification) or to a CT-
value of a known template concentration using a standard curve (absolute 
quantification). 
3.2.4 Gel electrophoresis 
Agarose gel electrophoresis was carried out for analytical purposes and for 
isolation of specific DNA-fragments. Corresponding to the size of the DNA-probes 
0.8% to 2% agarose gels were prepared with TAE buffer. To visualize the DNA 
fragments, 0.5 µg/ml ethidiumbromide was added to the liquid agarose. 
Ethidiumbromide intercalates into the stacked bases of the DNA molecule and 
emits orange light when illuminated with ultraviolet light (254 nm). For loading the 
DNA and to estimate the running time of the gel, gel- loading buffer was added to 
the DNA solution and standard size markers were used to determine the size of 
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the isolated bands. For cloning DNA fragments were excised from the gel and 
extracted with glass milk according to the manufacturer instructions. Gel 
electrophoresis of total RNA was performed in 1x TAE buffer. 
3.2.5 Laser capture microdissection. 
Sections for single cells or cell clones isolation from postnatal tissues were 
prepared as described above. Six-micrometer paraffin sections were transferred to 
PALM Membrane Slides (1mm glass slides covered with a 1.35 µm thin 
Polyethylene-naphthalate membrane) and let dry overnight at room temperature. 
Slides were deparaffinized, rehydrated and stained with Mayers Hematoxylin and 
Eosin Y as suggested from manufacturer. Cells were then captured with P.A.L.M. 
Microbeam System (Carl Zeiss MicroImaging GmbH) and digested in 20µl of 
buffer containing 50 mM Tris HCl pH8, 0.5 % Tween20 and 0.1µg/µl Proteinase K 
for one hour at 60°C. Proteinase K was then inactivated for 30 minutes at 85°C 
and PCR reaction was performed directly on the cell lysate. 
3.2.6 Sequencing 
Sequencing was carried out by GATC Biotech. 
3.2.7 Determination of the concentration of nucleic acids 
To quantify the amount of DNA or RNA, the optical density of probes was 
measured with a photometer at a wavelength of 260 nm. For DNA (double strand) 
the OD260= 1 corresponds to a concentration of 50 µg/ml, for RNA the OD260= 1 
corresponds to a concentration of 40 µg/ml. The relation of the absorption at 260 
nm and 280 nm describes the purification grade of the nucleic acids and should 
not exceed 2.0. 
3.2.8  Cell culture 
3.2.8.1 Endothelial cell isolation 
To distinguish endothelial cells from the micromass cultures I used endothelial 
cells expressing green fluorescent protein (GFP). Using an antibody against 
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VEGFR2 and MACS magnetic beads (Miltenyi Biotech) GFP endothelial cells were 
isolated from B5/EGFP mice between E12.5 and E13.5, which express GFP under 
the control of the β-actin promoter (Hadjantonakis et al 1998). Embryos were 
isolated, dissected and digested for 45 minutes with 2mg/ml Collagenase at 37°C, 
flipping tubes every 10 minutes. Each embryo was processed singularly. Cells 
were passed through a cell strainer (40µm) and seeded on a 75cm2 and let adhere 
O/N. On the next day cells were washed with 1X PBS and trypsinized. Cells were 
then washed in cell isolation buffer, centrifuged 10 minutes at 4°C at 1000rpm and 
then incubated in 200µl isolation buffer with anti-mouse Flk1 (BD Pharmingen) 
diluted 1:40 for 30 minutes at 4°C with agitation. Cells were again washed in cell 
isolation buffer, centrifuged 10 minutes at 4°C at 1000rpm and then resuspended 
in 80µl isolation buffer and 20µl goat anti-rat IgG microbeads (MACS Miltenyi) 
were added. After incubation at 4°C for 30 minutes on agitation, cells were washed 
again, resuspended in 500µl isolation buffer and applied onto a mini Macs column 
(Miltenyi) for magnetic separation. Columns were washed 3 times with 500µl 
isolation buffer and eluted with 1ml buffer. Cells were then seeded onto 25cm2 
flask (Corning) pre-coated with Collagen I from rat tail. For coating 0.5mg/ml Rat 
tail collagen type I (BD bioscience) diluted in 1XPBS (Invitrogen (Gibco)) was 
incubated at 37°C overnight. 
3.2.8.2 Micromass culture 
Micromass cultures are high density culture of limb mesenchymal cells. These 
undergo condensation giving rise to aggregates that later become cartilage 
nodules, mimicking chondrocyte differentiation in vivo. All four limb buds of E12.5 
mice were collected and washed in sterile 1xPBS. Each embryos was processed 
singularly and digested with 500µl/4limbs 1U/ml dispase(Neutral protease, Serva) 
in 1xPBS for 15 minutes at 37°C. Limbs were then washed 3 times with 1X PBS to 
remove the ectoderm and digested for 30 minutes with collagenase digestion 
solution for 30 minutes at 37°C. Cells were then passed through a cell strainer 
(40µm), washed with 10ml medium, counted with a Neubauer chamber, and 
centrifuged 5 minutes at 1000rpm. Cells were then resuspended at a 
concentration of 2x107/ml in DMEM/F12, 20µl were seeded on 12 well plates and 
incubated 2 hour at 37°C. Cells were then fed with 1.5 ml micromass medium and 
changed every second day for 5 weeks. 
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3.2.8.3 Boyden chamber assay 
Boyden chamber assay is used to test chemotactic behavior in the presence of 
different chemoattractants. It consists of two compartments separated by a pore 
filter. The chemotactic factor is placed in one compartment and the gradient 
develops across the thickness of the filter. Cell movement into the filter is 
measured after an incubation period less than the time taken for the gradient to 
decay. In my experiment I used as chemoattractant source micromasses from 
Ext1Gt/Gt mutants and control littermates. 
Both micromasses and endothelial cells were starved for 24 hours in basal 
medium supplemented only with pen strep. Endothelial cells were then trypsinized, 
resuspended in DMEM/F12 at a concentration of 2x104 /ml and 500µl were 
seeded onto a cell culture insert (BD falcon353182) which was placed directly on 
the micromass cultures. DMEM/F12 and DMEM/F12 supplemented with 20ng/ml 
VEGF (Human VEGF-A Peprotech) were used as negative and positive controls. 
Boyden chamber were incubated for 24 hours (as previously described Sansone 
et al. 2007) at 37°C and inserts were then placed in a new 12 well plate. Non 
migrated cells from the upper side on the membrane were wiped off and GFP 
positive cells were counted at fluorescent microscope at a wavelength of 488nm. 
Ten fields at 20x magnification for each well and each insert were counted. Cells 
were then fixed in ice cold methanol for 10 min and methanol was replaced with 
sterile water and stored at 4°C. 
3.2.8.4 Alcian blue staining of micromasses 
Alcian blue is a cationic dye, which stains acid mucopolysaccharides and 
glycosaminoglycans. Micromass cultures were washed with 1xPBS, fixed for 10 
minutes with 4%PFA and stained with Alcian blue staining solution overnight at 
RT. Next day cells were then washed 3 times and stored in sterile water at 4°C. 
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3.2.9 Histology and skeletal staining 
3.2.9.1 Skeletal staining 
Mice were killed by asphyxiation with CO2, skin and inner organs were removed. 
Full skeleton were then fixed with 100% EtOH for 2 days and placed in Alcian blue 
to stain proteoglycans for 24 hours. Then shortly washed with EtOH to remove rest 
of Alcian blue and cleared in 2%KOH for 24 hours. Skeleton were then placed in 
Alizarin red staining solution, to detect calcium deposits for at least 6 hours and 
then again in 2%KOH. Skeletons were then embedded in 100% Glycerol, after 
ascending series of KOH-glycerol mixture (2%KOH:Gly v/v: 80:20, 60:40, 40:60, 
20:80) 
3.2.9.2 Harvesting and processing of murine tissue 
Limbs were either fresh frozen in OCT embedding medium at -60°C for 
cryosectioning, or fixed in 4% PFA at 4°C overnight for embedding into paraffin. 
Tissue was rinsed three times with PBS for 5 minutes. Tissue of E14.5 and E16.5 
limbs was dehydrated for 10 minutes in 30%, 50%, 75%, 80%, 95% and 100% 
ethanol and subsequently incubated twice in 100% xylol. Then three changes of 
100% paraffin for 2 hours each followed. Limbs were embedded into paraffin and 
sectioned into 5 µm slices for 4-5 parallel sections, which were placed on silanized 
slides. Mice at embryonic stage 7.0 were dissected together with the maternal 
decidua out of the uterus, fixed overnight at 4°C in 4% PFA, included in paraffin 
and sectioned at 5µm. 
Knees from postnatal stages were harvested fixed in 4% PFA in PBS and 
decalcified in 25% EDTA (pH 7.4) at 37°C. Samples were processed to be 
embedded into paraffin as described above. Five- to 10-µm sections from paraffin-
embedded tissue were used for histology, in situ hybridization, 
immunohistochemistry and LCM.  
3.2.9.3 Hematoxylin/Eosin staining 
This histological staining method stains nuclei blue (Hematoxylin) and the 
cytoplasm red (Eosin). Sections were deparaffinized, rehydrated and subsequently 
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incubated for 45 seconds in Harris Hematoxylin (Sigma), rinsed shortly with tab 
water and then incubated for 2 to 3 minutes in Y Eosin (Sigma). Finally slides were 
rinsed with tab water, dehydrated by an increasing ethanol series, transferred into 
Xylol and embedded in DPX mounting medium. 
3.2.9.4 Tartrate resistant acid phosphatase (TRAP) staining 
Osteoclasts are characterized by the production of the enzyme tartrate resistant 
acid phosphatase (TRAP). Sections were deparaffinized, rehydrated and 
incubated 15 min at RT with TRAP staining solution washed twice with bidest 
water and mounted with water based mounting medium, Kaiser Gelatin. 
3.2.9.5 Von Kossa staining 
This technique is for demonstrating deposits of calcium or calcium salt so it is not 
specific for the calcium ion itself. In this method, tissue sections are treated with a 
silver nitrate solution and the silver is deposited by replacing the phosphates 
reduced by the strong light, and thereby visualized as metallic silver. Sections 
were deparaffinized, rehydrated and incubated 5 minutes in 1%AgNO3 under UV 
light. Slides were then washed 3 times in 5% sodiumthiosulfate and 3 times in 
bidest water. Slides were counterstained with Methyl green, dehydrated by short 
incubation in ascending alcohol series and transferred in xylol and embedded in 
DPX mounting medium. 
3.2.9.6 Toluidine blue staining 
Toluidine blue should stain proteoglycans red-purple and the background blue. 
Sections were deparaffinized, rehydrated and incubated in 0.2% Toluidine blue for 
5 minutes and dehydrated in ethanol solutions 30%, 50%, 75%, 80%, 95% and 
100%. The sections were incubated in 100% xylol and then covered with glass 
coverslips using minimal volume of mounting medium (DPX mountant for 
histology). 
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3.2.9.7 SafraninO staining 
This method is used for the detection of cartilage, mucin, and mast cell granules 
on formalin-fixed, paraffin-embedded tissue sections. The cartilage and mucin will 
be stained orange to red, and the nuclei will be stained black. The background is 
stained green. 
Sections were deparaffinized, rehydrated and stained with Weigert’s iron 
hematoxylin working solution for 10 minutes. Sections were washed in running tap 
water for 10 minutes and then stained with fast green (FCF) solution for 5 minutes. 
Slides were rinsed quickly with 1% acetic acid solution for no more than 10 –15 
seconds and then stained in 0.1% safranin O solution for 5 minutes. Sections were 
dehydrated and cleared with 95% ethyl alcohol, absolute ethyl alcohol, and xylol, 
using 2 changes each, 2 minutes each and mounted using DPX medium.  
3.2.9.8 CD31 immunohistochemistry. 
CD31 is a 130 KDa integral membrane protein, also known as platelet endothelial 
cell adhesion molecule 1 (PECAM1). CD31 is expressed constitutively on the 
surface of adult and embryonic endothelial cells (Huss et al., 2001; Vecchi et 
al.,1994; Vanzulli et al., 1997; Delisser et al., 1997). Limbs were sectioned at 5µm 
with a Microm cryostat. Sections were then fixed for 10 minutes in ice cold acetone 
and rehydrated for 5 minutes in 1xPBS. Endogenous peroxydase was blocked by 
incubation with 0.2% H2O2 in 1xPBS for 5 minutes. After washing in 1xPBS 
containing 0.5% BSA for 5 minutes primary antibody rat anti-mouse CD31 
(PECAM) (BD Pharmingen) diluted 1:70 in 1xPBS/0.5%BSA was incubated for 1 
hour at RT. After washing 3 times for 5 minutes with 1xPBS/0.5%BSA slides were 
incubated with secondary antibody rabbit anti-rat HRP, diluted 1:70 
1xPBS/0.5%BSA for 45 minutes at RT. After washing section were incubated 5 
minutes with diaminobenzidine (DAB) substrate and embedded with Kaiser 
Gelatin. 
3.2.9.9 Heparan sulfate immunohistochemistry 
Heparan sulfate can be detected with different antibodies which recognize specific 
patterns of differentially sulfated motives. The 10E4 antibody recognize (GlcA-
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GlcNS)/( GlcA-GlcNAc) mixed sequences and the HepSS1 antibody recognize 
(GlcA-GlcNS)-rich sequences. 
Sections were deparaffinized, rehydrated and washed 5 minutes in 1XPBS pH 7.4. 
Slides were then incubated in a humified chamber for 30 min at 37°C with 10000 
U/ml hyaluronidase I (from bovine testis SIGMA) in 1XPBS pH7.4. After washing 3 
times 5min in 1XPBS pH7.4 endogenous peroxydase was inactivated for 30 min at 
RT with 3% H2O2 in 1xPBS. After washing 3 times 5min in 1xPBS pH7.4 
unspecific binding was blocked for 30 min at RT in Blocking solution (10% goat 
serum in 1x PBS). Primary antibody 10E4/HepSS1 (Seikagaku, Japan) diluted 
1:100 in blocking solution was incubated O/N at 4°C. On the next day slides were 
washed 3 times for 5min in 1xPBS pH7.4. Incubation followed with Goat 
biotinylated secondary antibody against mouse IgM (Vector Laboratories) diluted 
1:100 in blocking solution for 30 min at RT. After washing slides were incubated 30 
min with Streptavidin-HRP (Perkin-Elmer) diluted 1:100 in 1xPBS. Slides were 
washed 3 times for 5 minutes in 1xPBS and then incubated with DAB for 5 
minutes. Sections were then counterstained with methyl green or directly mounted 
with Kaiser Gelatin. 
3.2.9.10 Methyl green staining 
Methyl green is used a counterstaining for immunohistochemistry or other special 
stains. After section were deparaffinized and rehydrated, they were stained in 
methyl green solution for 5 minutes at room temperature. After rinsing in distilled 
water slides were dehydrate quickly through 95% alcohol (10 dip), 2 changes of 
100% alcohol (10 dips each). Then sections were cleared in xylol and mounted 
with DPX. 
3.2.9.11 VDIPEN immunohistochemistry 
Degradation of the articular aggrecan leads to production of specific catabolic 
fragments, which accumulate in the matrix. Specific epitopes are generated, which 
are better known as VDIPEN and NITEGE, referring to the aminoacidic sequence 
produced from Mmps or aggrecanases cleavage. Aggrecan degradation have 
been intensely studied during the past few years (Lark et al., 1997, Westling et al., 
2002, Valverde-Franco et al.,2006, Fosang et al., 1995, Mercuri et al., 1999). 
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Sections were deparaffinized, rehydrated and digested with 0,25 U/ml 
chondroitinase ABC (Sigma) in 0.1M Tris-HCl, pH8.0 for 1 hour at 37°C to remove 
chondroitin sulfate from the proteoglycans. Endogenous peroxydase was 
inactivated for 30 min at RT with 3% H2O2 in 1xPBS. And then washed for 5min in 
0.1% Triton X-100 (v/v) in 1XPBS pH7.4. After blocking for 30 min at RT in 
Blocking solution (10% goat serum in 1X PBS), slides were then incubated O/N 
with VDIPEN primary antibody (kindly provided from Amanda J. Fosang) at a 
concentration of 2µg/ml in blocking solution at 4°C. On the next day slides were 
washed 3times for 5min in 1xPBS pH7.4. Incubation followed with rat-HRP anti 
rabbit secondary antibody (DAKO) diluted 1:200 in PBS for 3 hours at RT. After 
washing slides were incubated with DAB for 5 minutes. Sections were directly 
mounted with Kaiser Gelatin. 
3.2.10 In situ Hybridization 
3.2.10.1 Preparation of DNA template for in vitro transcription 
Plasmid DNA was isolated from E.coli DH5 cells using QIAprep Plasmid Miniprep 
or Midiprep Kits according to the manufacturer instructions. 5 µg plasmid DNA was 
linearized with 5 U of the appropriate restriction endonuclease for 2 hours at 37°C. 
Efficiency of the digestion was analyzed on a 1% agarose gel. For purification 
phenol/chloroform extraction was performed twice. The final supernatant was 
transferred to a clean tube and was precipitated with 2.5V of 100% ethanol. The 
mixture was centrifuged at 14.000 rpm for 15 minutes at room temperature (RT). 
The DNA pellet was washed with cold 80% ethanol and resuspended in 10 µl of 
RNAse free water. 
3.2.10.2 Labeling of antisense riboprobes 
Transcription reaction was performed in 20 µl with the following components: 500 
ng linearized DNA template for in vitro transcription, 1x transcription buffer, 0.5 
mM NTP mix, 5 U RNAse inhibitor, RNAse free water, 40 U RNA-polymerase and 
80 µCi [P33]-UTP. The transcription reaction was carried out for 1.5 hours at 37°C. 
To remove the DNA template, 10 U DNAse (RNAse- free) were added to the 
transcription mixture and incubated for 30 minutes at 37°C. The transcription 
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mixture was then diluted with 4 V of RNAse free water, containing 20 ng/ml 
glycogen and 0.5 M LiCl, and precipitated with 2.5 V of 100% ethanol. Probes 
were incubated at -20°C for 30 min and then centrifuged at 14.000 rpm for 15 
minutes at 4°C. The RNA pellet was washed twice with cold 80% ethanol, 
resuspended in 50 µl RNAse free water, and diluted 1: 20 with hybridization buffer. 
Before use the riboprobe was heated for 5 minutes at 95°C and chilled on ice. 
3.2.10.3 Prehybridization and in situ hybridization 
All solutions for the prehybridization procedure were prepared with RNAse free 
water. The sections were incubated in xylol for 30 minutes to remove the paraffin. 
To rehydrate the tissue, the sections were incubated in a descending ethanol 
series (100%, 95%, 80%, 75%, 50%, 30%) each for 2 minutes, followed by 0.85% 
NaCl for 5 minutes and PBS for 5 minutes. After rehydration the tissue was fixed in 
4% PFA for 30 minutes. The sections were then incubated for 5 minutes in 
following solutions: PBS, 0.2N HCl and RNAse free water. The tissue was 
digested for 5 minutes with 0.02 mg/ml Proteinase K and rinsed with PBS for 5 
minutes. Subsequently the sections were refixed in 4% PFA with 0.2% 
glutaraldehyde for 10 minutes and rinsed with PBS for 5 minutes. The sections 
were acetylated by 0.25% acetic anhydride (freshly added) to 0.2% 
Triethanolamine for 10 minutes, then rinsed with PBS for 5 minutes and 
additionally incubated in 0.85% NaCl for 5 minutes. Sections were dehydrated with 
the following ethanol solutions: 30%, 50%, 75%, 100%. The sections dried at RT 
for 15 minutes. A minimal volume of labeled riboprobe (50µl) was distributed 
evenly on the slide and the sections were covered with plastic coverslips to 
prevent evaporation. Hybridization was performed at 70°C overnight. 
After hybridization the sections were washed in 5xSSC for 30 minutes and 
coverslips were removed. The sections were washed in 2xSSC for 30 minutes and 
treated with 0.02mg of RNAse A in 1x Washing buffer for 30 minutes. Stringent 
washing took place in 2xSSC with 50% formamide for 30 minutes and then twice 
in 2xSSC for 30 minutes. The sections were dehydrated in an ascending ethanol 
series (30%, 50%, 75%, 80%) containing 0.3M ammonium acetate. Finally the 
sections were incubated in 100% ethanol for 15 minutes and dried for 10 minutes 
at RT. The slides were exposed to a X-ray film (Kodak Scientific Imaging Film) 
overnight at RT to estimate the intensity and strength of each probe. The sections 
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were dipped in photoemulsion NTB2 at 40°C in the darkness. Dried sections were 
stored at 4°C in darkness for the time predicted from the developed X-ray film. The 
dipped sections were developed in Kodak-developer for 5 minutes at 15°C, rinsed 
in water and fixed in Kodak- fixer for 15 minutes at RT. The sections were 
counterstained with 0.2% Toluidin blue O for 5 minutes and dehydrated in ethanol 
solutions 30%, 50%, 75%, 80%, 95% and 100%. The sections were incubated in 
100% xylol and then covered with glass coverslips using minimal volume of 
mounting medium (DPX mountant for histology). The sections were analyzed by 
dark- field microscopy. 
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4. Results  
4.1 Endochondral ossification in Ext1Gt/Gt. 
4.1.1 Osteoblast and osteoclast invasion are perturbed in Ext1Gt/Gt 
mutants. 
Mutations in the human EXT1 and EXT2 genes lead to the formation of human 
osteochondromas. However, the cellular and molecular causes of the disease 
have yet to be identified. These include the cell type that gives rise to the 
osteochondromas and the allelic status of EXT1 in the cells, which will form the 
tumor. Previous studies based on morphological investigations of early human 
osteochondromas biopsies pointed to either chondrocytes of the growth plate or 
osteoblast progenitors of the perichondrium/periosteum as potential candidates 
(Delgado et al., 1987; Hameetman et al., 2007; Robinson et al., 1999). Analysis of 
a hypomorphic allele of Ext1 in mice revealed that chondrocyte differentiation is 
severely delayed (Koziel et al., 2004) in homozygous mutants indicating that 
osteochondromas might originate in proliferating/differentiating chondrocytes. 
However, preliminary investigations revealed that the ossification process and the 
invasion of blood vessels seem to be disturbed in the mutant skeletal elements. To 
investigate if disturbed ossification or vascular invasion might contribute to 
osteochondroma development we first investigated the role of Ext1 in regulating 
these processes in detail. 
As targeted deletion of Ext1 (Ext1-/-) is lethal during gastrulation (Lin et al., 2000; 
Stickens et al., 2005) I analyzed mineralization and vascular osteoclast invasion in 
a mutant mouse carrying a hypomorphic allele of Ext1 (Ext1Gt/Gt). These mice 
survive until E16.5, the stage at which primary ossification centers have formed in 
wild type (wt) mice (Fig. 9). The deletion of Ext1 in these mice has been generated 
by the insertion of a gene trap vector into the first intron of Ext1, creating a 
truncated Ext1 protein fused to the ß-geo reporter of the vector (Leighton et al., 
2001) (Fig. 9). Ext1Gt/+ mice show no obvious phenotype, develop normally and 
are viable (Koziel et al., 2004). Therefore in the present study Ext1Gt/+ mice have 
been used as control littermates, and are referred to as wt.  
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Figure 9. Hypomorphic allele of Ext1. Schematic representation of the Ext1 gene and 
the gene trap vector. The product of the hypomorphic allele is a truncated, non functional 
Ext1 protein. 
In wt mice the ossification process starts at E13.5 to E14.5 when chondrocytes in 
the center of the cartilage anlagen differentiate into ColX expressing hypertrophic 
chondrocytes. In parallel cells of the perichondrium differentiate into osteoblasts, 
secreting a Col1 rich mineralized matrix. Subsequently, the ColX rich cartilage 
matrix is degraded by multinucleated, bone resorbing cells, the osteoclasts, 
allowing blood vessels and osteoblasts to invade the skeletal anlagen. 
4.1.2 Expression of osteoblast markers and chondrogenic matrix 
degrading enzymes are not significantly delayed in Ext1Gt/Gt 
mice. 
To analyze the role of Ext1 during osteoblast differentiation, changes in the 
expression patterns of osteoblast markers were investigated by in situ 
hybridization in Ext1Gt/Gt mice (Fig. 10). At E14.5, before the primary ossification 
center forms, chondrocytes turn into hypertrophic and terminal hypertrophic cells 
expressing ColX and matrix metalloprotease 13 (Mmp13). In parallel, osteoblasts 
starting to differentiate in the perichondrium/periosteum express bone gamma-
carboxyglutamate protein (Bglap), a secreted protein implicated in bone 
mineralization and calcium homeostasis (Lee et al., 2000). At E16.5 a proportion 
of wt hypertrophic chondrocytes has differentiated into terminal hypertrophic cells 
resulting in two zones of Mmp13 expression separated by the bone marrow cavity 
(Fig. 10 B, D). Osteoblasts start to differentiate and deposits mineralized matrix, as 
shown by Bglap expression in the ossified center of the bone and the 
perichondrium/periosteum flanking the hypertrophic cells (Fig.10 F). ColX 
expression in the E16.5 mutant anlagen reveals hypertrophic differentiation of the 
chondrocytes. However the narrow distance between the two expression domains 
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in the Ext1Gt/Gt mutants (Fig. 10 A) indicates a severe delay, as also Ext1Gt/Gt 
mutants show only one zone of terminal hypertrophic chondrocytes expressing 
Mmp13, while Bglap expression is restricted to the perichondrium/periosteum 
(Fig.10 C, E). In summary, cartilage matrix resorption and osteoblast differentiation 
are both taking place in the anlagen of E16.5 Ext1Gt/Gt mutants, but both are 
delayed compared to wt embryos. This delayed expression of osteoblast markers 
in Ext1Gt/Gt mutants can be explained as a consequence of the general delay in 
chondrocyte differentiation, which has been described before (Koziel et al, 2004). 
 
Figure 10. Ossification is delayed in E16.5 Ext1Gt/Gt forelimb. In situ hybridization of 
ColX, Mmp13 and Bglap on wt (B, D, F) and Ext1Gt/Gt skeletal anlagen (A, C, E) revealed 
extended domains of hypertrophic chondrocytes (ColX and Mmp13 expression). Bglap 
expression demonstrates that ossification is restricted to the perichondrium/periosteum 
flanking the hypertrophic region in Ext1Gt/Gt mutant (E). Magnification 50X.  
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4.1.3 Endochondral ossification and osteoclast invasion are 
defective in Ext1Gt/Gt mice. 
Ext1Gt/Gt mice show delayed expression of osteoblast and hypertrophic 
differentiation markers compared to wt. Nonetheless gene expression can be 
considered normal in relationship to hypertrophic chondrocytes differentiation and 
delayed as a consequence of the primary delay, due to disturbed Ihh signaling 
(Koziel et al., 2004). Ossification and osteoclast invasion were morphologically 
analyzed in relationship to hypertrophic differentiation in Ext1Gt/Gt mutant and wt 
littermates at different stages, from E14.5 to E16.5 (Fig. 11). 
At E14.5 osteoblasts start to differentiate in the perichondrium/periosteum, 
secreting a Col1 rich mineralized matrix, which can be detected by von Kossa 
staining. In wt mice first mineralization of the perichondrium/periosteum can be 
detected at E14.5 (Fig. 11 B) and at E15.5 (Fig. 11 D) a few mineralized 
trabeculae have replaced the cartilage matrix. At E16.5 the zone of endochondral 
bone has expanded and wider mineralized trabeculae can be detected (Fig. 11 F). 
At E14.5 in Ext1Gt/Gt anlagen chondrocytes have not turned hypertrophic yet and 
mineralization has not started (Fig. 11 A). In Ext1Gt/Gt mutants first mineralization of 
the perichondrium/periosteum can be detected at E15.5 (Fig. 11 C, red arrow). At 
E16.5 the perichondrium/periosteum surrounding the hypertrophic zone is strongly 
mineralized and more mineralized trabeculae have substituted the cartilaginous 
matrix surrounding the hypertrophic chondrocytes (Fig. 11 E). 
Osteoclasts are characterized by the production of the enzyme tartrate resistant 
acid phosphatase (TRAP). In wt mice, first osteoclast invasion can be detected at 
E14.5 in the perichondrium surrounding the diaphyses of the skeletal elements 
(Fig. 11 H). At E15.5 osteoclasts have invaded the primary ossification center (Fig. 
11 J) and at E16.5 the zone of endochondral bone has expanded and more 
osteoclasts can be detected (Fig. 11 L). The Ext1Gt/Gt mutants show delayed 
osteoclast invasion at the primary ossification center. At E14.5 and E15.5 the 
Ext1Gt/Gt mutant skeletal anlagen is devoid of osteoclasts (Fig. 11 G, I). Only at 
E16.5 single osteoclasts can be detected that start to invade the diaphyses of 
Ext1Gt/Gt mutants (Fig. 11 K, red arrows). In summary osteoclast invasions and 
mineralization are delayed in Ext1Gt/Gt mutants.  
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Fig. 11. Osteoblast differentiation and osteoclast invasion are delayed in Ext1Gt/Gt 
skeletal elements. Von Kossa staining of Ext1Gt/Gt and wt skeletal elements (A-F) reveals 
that the mineralization of Ext1Gt/Gt mutant radii (A, C and E) is severely delayed compared 
to wt radii (B, D and F). At E15.5 and E16.5 the wt elements (D, F) show mineralized bone 
matrix and a bone marrow cavity between two zones of hypertrophic chondrocytes. At 
E15.5 the Ext1Gt/Gt mutant (C) shows no mineralization except of a weak staining of the 
perichondrium/periosteum (C, red arrow). At E16.5, hypertrophic cells are still surrounded 
by a mineralized matrix In the Ext1Gt/Gt mutants and skeletal elements are lacking a bone 
marrow cavity, which in wt mice is has started to form at E15.5 (D). TRAP staining (G-L) 
of E14.5 to E16.6 Ext1Gt/Gt mutant radii (G, I, K) show no osteoclast invasion compared to 
wt radii (H, J, L). At E14.5 wt skeletal elements show osteoclast invasion of the 
perichondrium/periosteum (H). At E15.5 and E16.5 (J, L) a high number of osteoclasts 
can be detected in the center of the wt anlagen. E14.5 and E15.5 Ext1Gt/Gt mutants show 
no osteoclast invasion (G, I). Although chondrocytes have turned hypertrophic in the 
mutant skeletal elements at E16.5 (K) only a few TRAP positive osteoclasts can be 
detected in the perichondrium/periosteum (K, red arrows). Magnification 200X.  
4.1.4 Development of the vascular plexus is disturbed in Ext1Gt/Gt 
mutants  
During the first stages of endochondral ossification the cartilage template is an 
avascular structure, which develops into a hollow and highly vascularized element, 
the marrow cavity (Karsenty and Wagner, 2002). Hypertrophic chondrocytes start 
to produce angiogenic factors, inducing the first capillary invasion of the cartilage 
template (Colnot and Helms, 2001; Zelzer et al., 2001). The vasculature supplies 
the template with cells belonging to the osteoblast and osteoclast lineage (Colnot 
et al., 2004; Zelzer et al., 2002). VEGF-A have been shown to directly enhance the 
resorption activity and survival of mature osteoclasts (Nakagawa et al., 2000). 
Osteoclasts express Flt-1 and Vegf-A from hypertrophic chondrocytes has been 
shown to be a chemoattractant for osteoclasts to invade the developing bone 
(Blavier and Delaisse, 1995; Engsig et al., 2000; Henriksen et al., 2003). The 
delay in gene expression observed in Ext1Gt/Gt mutants likely results from the delay 
in chondrocyte differentiation. Although osteoblast differentiation and cartilaginous 
matrix resorption in E16.5 Ext1Gt/Gt mutants have started, bone marrow cavity 
formation and osteoclast invasion of the cartilage anlagen are defective in Ext1Gt/Gt 
mutants. As a similar phenotype has been correlated to defective vascularization 
and disturbed VEGF-A protein distribution (Blavier and Delaisse1995; Engsig et 
al., 2000; Henriksen et al., 2003; Vu et al., 1998) I decided to investigate blood 
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vessels formation in the Ext1Gt/Gt mutants. Homozygous Ext1Gt/Gt embryos are 
characterized by an edematous appearance (Koziel et al., 2004; Lin et al., 2000) 
suggesting that blood vessels formation is also disturbed in these mutants. 
Vascularization was analyzed at E14.5 and E16.5 in wt and Ext1Gt/Gt mice, using 
an anti-CD31/PECAM antibody that specifically detects endothelial cells of the 
blood vessels (Fig. 12). In E14.5 wt embryos, blood vessels can be detected in the 
limb mesenchyme and in the perichondrium/periosteum surrounding hypertrophic 
chondrocytes (Fig. 12 B). In Ext1Gt/Gt mutants of the same stage, endothelial cells 
can be identified in the limb mesenchyme. However, they appear disorganized and 
proper vessels do not form (Fig. 12 A). Furthermore no invasion of the 
perichondrium/periosteum can be detected. At E16.5 a highly vascularized 
perichondrium/periosteum and bone marrow cavity have formed in wt embryos 
(Fig. 12 D, F). In contrast in Ext1Gt/Gt mutants no bone marrow cavity has formed 
and no invasion of the periosteum by endothelial cells can be detected (Fig. 12 C, 
yellow lines indicate borders of the anlagen). As revealed by Hematoxylin/Eosin 
staining Ext1Gt/Gt mutant blood vessels do not invade the mutant anlagen although 
at E16.5 chondrocytes have turned hypertrophic (Fig. 12 E). 
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Figure 12. Blood vessel formation is disturbed in Ext1Gt/Gt mutants. Cryosections of 
wt and Ext1Gt/Gt mutant radii at E14.5 and E16.5 were immunostained using an antibody 
against CD31/PECAM, a marker for endothelial cells and analyzed by H&E (A and C). 
Parallel sections of E16.5 Ext1Gt/Gt mutants (E) and wt radii (F) were stained with 
Hematoxylin/Eosin. In E14.5 wt embryos the periosteum is invaded by blood vessels (B). 
At E16.5 a highly vascularized region has developed in the center of the wt skeletal 
anlagen (D, F). Endothelial cells in the Ext1Gt/Gt mutant (A and C) do not form a proper 
vasculature. At E14.5 and E16.5 no invasion of the periosteum can be detected and the 
endothelial cells invasion has not taken place in the mutant skeletal element is devoid of 
blood vessels (A) and no blood vessel invasion can be observed at E16.5, although 
hypertrophic differentiation has taken place (C, E). Magnification 200X.  
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4.1.5 Expression of angiogenic markers is not disturbed in Ext1Gt/Gt 
mutant 
Blood vessel invasion of the periosteum is induced by the expression of 
angiogenic growth factors in hypertrophic chondrocytes. These factors signal to 
their receptors on endothelial cells in the surrounding tissue, inducing their 
migration into the ossifying perichondrium/periosteum. To examine if the defective 
angiogenesis results from changes in the expression of vascular endothelial 
growth factor A (VEGF-A) and its receptors Flt-1, Flk-1, and Nrp1, I analyzed the 
expression of these genes by in situ hybridization in E14.5 to E16.5 Ext1Gt/Gt 
mutant and wt forelimbs (Fig. 13 and 14). It has previously been shown that 
hypertrophic chondrocytes express Vegf-A and Nrp1, while the receptors 
VegfR2/Flk1 and VegfR1/Flt1 are expressed on endothelial cells in the 
surrounding tissue starting at E14.5. Upon formation of the periosteum at E15.5 
both receptors can be detected on EC invading the ossified region. At E16.5 the 
expression of both receptors is additionally increased in the bone marrow and at 
the interface between bone marrow and terminal hypertrophic chondrocytes, while 
Vegf-A and Nrp1 expression remains unchanged (Zelzer et al., 2002). Consistent 
with published data, overlapping expression of Vegf-A and ColX, is found in 
hypertrophic chondrocytes of E14.5 wt mice (Fig. 13 B, D). At this stage Nrp1 
expression cannot be detected in the cartilage anlagen of radius and ulna but is 
strongly expressed in the joint interzone of the digits (Fig. 13 J, red arrow). Flk1 
and Flt1 are strongly expressed in the tissue surrounding the skeletal elements 
and in the perichondrium (Fig. 13 F, H). In Ext1Gt/Gt mutants only few chondrocytes 
express ColX and Vegf-A, in relation to the delay in hypertrophic differentiation 
(Fig. 13 A, C). In contrast to the wt, Nrp1 is not expressed in the mutant digits (Fig. 
13 J, I), while Flk-1 and Flt-1 are expressed in the surrounding mesenchymal 
tissue, similar to the wt (Fig. 13 E, F and G, H). In wt mice at E16.5 Vegf-A and 
Nrp1 are strongly expressed from hypertrophic chondrocytes (Fig. 14 B, D, J), 
while Flk-1 and Flt-1 are still expressed in the limb mesenchyme but strong 
expression can also be detected in the bone marrow cavity (Fig. 14 F, H). At E16.5 
Ext1Gt/Gt mutants show a strong overlapping expression of ColX, Vegf-A and Nrp1, 
delayed compared to wt littermates as a consequence of the delay in hypertrophic 
differentiation (Koziel et al., 2004) (Fig. 14 A, C, I and B, D, J). Flk-1 and Flt-1 
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expression is restricted to the perichondrium/periosteum in the Ext1Gt/Gt mutants 
and expression in the center of the anlagen is missing (Fig. 14 E, G).  
 
Figure 13. Expression of vascularization markers is not disturbed in Ext1Gt/Gt mutant 
forelimb at E14.5. Wt and Ext1Gt/Gt forelimbs were hybridized with riboprobes for ColX (A, 
B), Vegf-A (C, D) and the VEGFRs, Flk-1 (E, F), Flt-1 (G, H) and Nrp1 (I, J). Ext1Gt/Gt 
skeletal anlagen (A, C, E, G, I) show delayed expression of all markers expressed by 
hypertrophic chondrocytes (A, C, I), compared to wt mice (B, D, J). Furthermore Nrp1 is 
only expressed in the skin in the mutant (I) while it is expressed in the skin and in the joint 
interzone of the digits of the wt embryos (J, red arrows). VEGF-A receptors, Flk-1 and Flt-
1 are normally expressed in the mesenchymal tissue of the Ext1Gt/Gt mutants (E, G) similar 
to wt limbs (F, H). Magnification 50X. 
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Figure 14. Expression of vascularization markers in E16.5 Ext1Gt/Gt forelimbs is not 
disturbed. In situ hybridization of wt and Ext1Gt/Gt forelimbs with riboprobes for ColX (A, 
B), Vegf-A (C, D) and the VEGFRs, Flk-1 (E, F), Flt-1 (G, H) and Nrp1 (I, J). Expression of 
ColX, Vegf-A and Nrp1 (A, C, I) are expanded in Ext1Gt/Gt skeletal anlagen with two distinct 
ColX expression domains (A). However, expression in the mutant is still delayed 
compared to wt (B, D, J). Flk-1 and Flt-1 (F, H) are strongly expressed in the wt bone 
marrow cavity, while their expression is still lacking in the center of the Ext1Gt/Gt mutant 
anlagen (E, G, red arrows). Magnification 50X. 
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In summary, Ext1Gt/Gt mutants show disturbed blood vessels formation and no 
vascular invasion of the cartilage anlagen, although expression of angiogenic 
markers is not considerably delayed. This suggests that either the stabilization or 
the binding of VEGF-A might be altered by loss of HS. 
4.1.6 Ext1Gt/Gt chondrocytes induce increased migration of 
endothelial cells in vitro. 
Although in Ext1Gt/Gt mutants hypertrophic chondrocytes express Vegf-A and 
endothelial cells express the proposed receptors, blood vessel invasion of the 
differentiating periosteum flanking the hypertrophic region is severely delayed. As 
HS has been shown to mediate VEGF-A binding to its receptor the delay might be 
due to the reduced signal reception in the endothelial cells. In addition the release 
of VEGF-A by the chondrocytes might be altered to the reduced levels of HS in the 
Ext1Gt/Gt chondrocytes. To analyze the capacity of Ext1Gt/Gt mutant chondrocytes to 
induce endothelial cell migration a modified Boyden chamber assay was 
established. High density micromass cultures of primary limb mesenchymal cells 
(4x105 cells) were seeded in the bottom of the well of a 12-well culture plate. In 
such micromass cultures mesenchymal cells condense and differentiate into 
chondrocytes, forming so called “cartilage nodules”. The chondrocytes in these 
nodules have been shown to undergo the critical stages of differentiation including 
differentiation into hypertrophic chondrocytes thereby mimicking the in vivo 
chondrocyte differentiation process (Ahrens et al., 1977; Solursh et al., 1978). 
Micromass cultures differentiated for 5 weeks before Boyden chamber assay was 
performed. 
To distinguish endothelial cells from cells of the micromass cultures I isolated 
primary endothelial cells of a mouse line expressing green fluorescent protein 
(GFP) under the ubiquitous β-actin promoter (B5/EGFP mice) (Hadjantonakis et al 
1998). Using an antibody against VEGFR2 and MACS magnetic beads (Miltenyi 
Biotech) endothelial cells were isolated from E12.5 and E13.5 B5/EGFP mice. 
After one week of culture, endothelial cells were subjected to 24 hours of serum 
starvation. Then 104 GFP endothelial cells were seeded on the transwell plate 
filter, situated on top of the micromass cultures and let migrate through the filter 
toward the bottom of the well. 
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Migration towards the micromass cultures was analyzed after 24 hours by 
counting the number of cells found on the bottom side of the filter and on the 
micromass cultures (Fig. 15 A, B). As positive control migration towards 30ng of 
VEGF-A protein as attractive signal was analyzed.  
Interestingly migration towards the Ext1Gt/Gt mutant chondrocytes was significantly 
increased by 30% compared to wt (unpaired students T-test: n=7; p<0.0001) (Fig. 
15C). A Boyden chamber assay with 30ng of VEGF-A protein as attractive signal 
was used as positive control. Comparing the Boyden chamber assay for VEGF-A 
and Ext1Gt/Gt micromasses I can conclude that endothelial cells have migrated 
60% more towards Ext1Gt/Gt mutant cells than to VEGF-A in 24 hours. In contrast 
the control micromasses induce an increased migration up to 45% in 24hours 
compared to VEGF-A protein. 
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Figure 15. Increased migration of endothelial cell towards Ext1Gt/Gt mutant 
micromasses. 24 hours Boyden chamber assay with endothelial cells expressing GFP. 
Representative pictures of migrated GFP-endothelial cells on micromass cultures of 
Ext1Gt/Gt mutant (A) or wt micromasses (B). Red arrow in B shows an adherent endothelial 
cell on wt culture. Magnification 100X. (C) Endothelial cell migration showed a 30% 
increase toward Ext1Gt/Gt micromass cultures compared to wt cultures. (Y axis: number of 
migrated endothelial cells) (n=7; *: p < 0.02 unpaired student's t test).  
 
In order to test if the increased migration of endothelial cells is a consequence of 
an increased Vegf-A expression in the mutant micromass cultures, quantitative 
reverse transcription PCR (qRT-PCR) was performed using cDNA of the same 
micromass cultures. No significant alterations in the expression levels of Vegf-A, 
ColX and Bglap (Osc) could be detected (unpaired Student t-test: n=7 p>0.05) 
(Fig. 16C), indicating that the increase in endothelial cell migration towards the 
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Ext1Gt/Gt mutant chondrocytes is not due to an increase in VEGF-A transcript. 
Alcian blue staining on micromass cultures show high number of chondrogenic 
nodules in the mutant micromasses, while the wt cultures show few nodules and 
presence of hypertrophic cells (Fig.16 A, B). The expression analyses revealed a 
significant increase in Col2 expression in Ext1Gt/Gt micromasses (p<0.05; n=7) 
which correlate with the strong Alcian blue staining that reflects the presence of 
cartilaginous nodules. 
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Figure 16. Increase in endothelial cell migration is not due to increase in VEGF-A 
expression in Ext1Gt/Gt mutant micromasses. Alcian blue staining of Ext1Gt/Gt mutant (A) 
and wt micromasses (B). Strong Alcian blue staining of the Ext1Gt/Gt mutant micromasses 
(A) reveals high number of chondrogenic nodules. In contrast wt micromasses show only 
few nodules and hypertrophic chondrocytes (B). Gene expression analyses by 
quantitative real time PCR (qPCR) (C). qPCR evaluation shows that Ext1Gt/Gt mutant 
cultures express similar level of ColX, Vegf-A and Bglap (Osc) compared to wt 
micromasses (p>0.05; n=7). However Col2 expression is upregulated in the Ext1Gt/Gt 
mutant cultures. (*; p<0.05; n=7)(Y axis represent increase fold values). (Magnification 
40X). 
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4.2 Analysis of an Ext1 mouse models for Multiple 
Osteochondromas  
4.2.1 Gene targeting strategy and disruption of Ext1 function 
The early lethality of Ext1Gt/Gt mice limits their use as a model for studying 
osteochondroma development. In order to investigate the generation of exostoses, 
I analyzed a mouse model in which the Ext1 gene can be conditionally inactivated, 
kindly provided by Dr. Kevin B. Jones (University of Utah). These mice carry two 
trans orientated loxP sites flanking the second exon of the Ext1 gene, and a NEO 
cassette, flanked by an additional loxP site cis-orientated to the second loxP site 
(Ext1e2neofl/e2neofl) (Fig. 17). Cre-induced recombination of the allele generated 8 
different allelic recombinations of the transgene. To establish a mouse line lacking 
the NEO cassette, Ext1e2neofl/e2neofl males were crossed to Prx1-Cre females, which 
express Cre recombinase in the germ line (Logan et al., 2002). Twenty litters were 
genotyped by PCR to identify mice that had lost the neo cassette and retained the 
second exon in either wt (Ext1e2fl/+) or inverted orientation (Ext1e2flinv/+) (Fig. 17). 36 
out of 127 mice carried the wt allele and 26 the inverted. These two mouse lines 
were crossed to C57BL6/J wt mice for two generations, to verify stable germ line 
transmission of the targeted allele. Both Ext1e2fl/+ and Ext1e2flinv/+ mice are born at 
the expected Mendelian ratios.  
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Figure 17. Generation and characterization of head-to-head floxed Ext1 allele: 
deletion of the neomycin resistance gene and generation of a non functional Ext1 
allele. Ext1e2neofl/e2neofl mice carry two loxP sites, trans-orientated, flanking the second exon 
of the Ext1 gene, and a NEO cassette, flanked by a third loxP site cis-orientated to the 
second loxP site. The neomycin resistance gene was deleted by crossing Ext1e2neofl/e2neofl 
males to Prx-1 Cre females expressing Cre recombinase in the germ line. 
In order to confirm that the inversion of exon 2 results in a loss of Ext1 function 
allele sections of homozygous Ext1e2flinv/e2flinv embryos, derived from crosses of 
Ext1e2flinv/+ mutants, were analyzed at embryonic stage E7,0 (Fig. 18) with 
Hematoxylin/Eosin staining. Four out of 10 embryos were smaller and failed to 
undergo gastrulation, consistent with the phenotype previously described for Ext1-/- 
and Ext2-/- null mutant mice (Stickens et al., 2005; Lin et al., 2000). Genotyping, 
performed by nested PCR on carefully dissected embryonic tissues, confirmed 
that these embryos were homozygous Ext1e2flinv/e2flinv mutants. In wt embryos the 
structures typical for this stage of development can be subdivided into the extra 
embryonic compartment and structures of the embryo proper (Fig.18 B). The 
posterior end of the primitive streak (ps) bulges into the proamniotic cavity (pc) 
forming the posterior amniotic fold. In the mesoderm of the posterior amniotic fold, 
small cavities coalesce to form a single cavity, the exocoelom (ec). In the 4 
Ext1e2flinv/e2flinv mutant embryos it was not possible to distinguish between extra 
embryonic structures and the embryo proper (Fig. 18 A). To exclude that these 
mutants produced functional Ext1 protein, the amount of HS was analyzed by 
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immunohistochemistry using an antibody for the 10E4 epitope, which recognize 
alternating D-glucuronic acid and N-acetyl-D-glucosamine residues of HS (Fig. 18 
C, D). Wt and heterozygous mice showed strong staining of HS in all embryonic 
and extra embryonic tissues (Fig. 18 D), while no HS sulfate could be detected in 
the homozygous Ext1e2flinv/e2flinv mutants. 10E4 staining was however detected in 
the surrounding placenta (Fig. 18 C), which partly consists of heterozygous 
maternal tissue and can be considered as internal positive control. 
In summary, these results show that when exon 2 of Ext1 is inverted, it results in a 
loss of function of Ext1 allele and abolishes the production of HS.  
 
Figure 18. Inversion of exon2 of Ext1 generates a loss of function of the Ext1 allele. 
Hematoxylin/Eosin staining (A and B) and immunohistochemistry with the 10E4 antibody ( 
C and D) of E7.0 frontal sections of wt (B and D) and Ext1e2flinv/e2flinv embryos (A and C) 
demonstrated failing gastrulation and reduced HS in the embryonic tissue (A and C, 
arrows) of Ext1e2flinv/e2flinv mice, whereas placental tissues showed intensive staining for HS 
(ec, exocoelomic cavity; pc, proamniotic cavity; e, ectoderm; ps, primitive streak; bs, 
basement membrane; en, endoderm). Magnification 200X. 
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4.2.2 Postnatal inactivation of Ext1 generates exostoses.  
To investigate if clonal somatic loss of Ext1 leads to osteochondroma formation, 
the Ext1 gene was deleted in proliferating chondrocytes by crossing homozygous 
Ext1e2fl/e2fl mutants to mice carrying a Cre recombinase allele under the control of a 
tetO heptad minimal cytomegalovirus (CMV) promoter and a rtTA (tetracycline 
reverse transcriptional activator) gene under the control of a Col2 promoter (Col2-
rtTA-Cre; Grover and Roughley, 2006). In the resulting Col2-rtTA-Cre;Ext1e2fl/e2fl 
mice doxycycline treatment activates the rtTA reverse repressor that is expressed 
in Col2 expressing cells. The activated rtTA in turn induces the expression of Cre 
recombinase by binding the tetO/CMV promoter. Consequently, exon 2 of the Ext1 
gene is inverted in Col2 expressing chondrocytes after administration of 
doxycycline (Fig. 19). 
  
Figure 19 Somatic inactivation of Ext1 in proliferating chondrocytes. Ext1e2fl/e2fl mice 
were crossed to a mouse line carrying a doxycycline inducible Cre recombinase gene 
under the control of the Col2 promoter (Col2-rtTA-Cre). Doxycycline binds to the reverse 
transcriptional tetracycline repressor (rtTA), which is produced in Col2 expressing 
chondrocytes. The activated rtTA binds to the tetO/CMV promoter and activates the 
expression of Cre recombinase. This enzyme recombines the trans-orientated loxP sites 
resulting in an inversion of the genomic sequence flanked by the two loxP sites. 
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In previous experiments 4mg/ml doxycycline in drinking water has been 
administrated to lactating mothers starting at postnatal day 8 (P8) over a period of 
8 days. Using this protocol, massive exostoses were generated at all metaphyses 
of the long bones, leading to severe bone malformations (K. B. Jones personal 
observations). In order to induce a controlled, less severe phenotype I established 
a protocol to induce reduced numbers of osteochondromas with 100% penetrance. 
The following treatment strategies were compared:  
1) 4 mg/ml doxycycline in 5% sucrose through the drinking water for 8 days 
2) 4 Intraperitoneal (IP) injections of 80µg doxycycline /gram body weight (gbw)  
3) 2 IP injections of 80µg doxycycline /gbw  
4) 1 IP injection 80µg doxycycline /gbw  
Histological analyses of sections through hindlimbs of 8 weeks old mice after 
induction revealed that all treatment strategies resulted in the reproducible 
induction of the exostoses in all cases investigated. As the malformations of the 
long bones seemed to be less severe in the shortest treatment period a single IP 
injection of 80µg doxycycline/gbw was used in all further experiments (Fig. 20).  
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Figure 20. Histological analyses of femurs of Col2-rtTA-Cre;Ext1e2fl/e2fl  mice induced 
with different doxycycline administrations. Col2-rtTA-Cre;Ext1e2fl/e2fl  mice treated 8 
days with 4 mg/ml doxycycline, administered through drinking water, (A) or one IP 
injection of 80µg doxycycline/gbw (B) were sacrificed at 8 weeks of age. Both treatment 
strategies resulted in the development of ostechomdromas. Red arrows indicate 
exostoses arising at the side of the growth plate. Magnification 25X. 
To analyze the development of osteochondromas animals were sacrificed at 
different time points after the doxycycline treatment (4, 5, 6 and 8 weeks old mice). 
In the course of the study knees were collected and processed for further 
analyses. Histological anaysis on H&E stained serial sections of the knees shows 
development of osteochondromas in homozygous Ext1e2fl/e2fl mice, which carry the 
Cre recombinase under the Col2 promoter (Col2-rtTA-Cre) with a frequency of 
100%. None of the animals that did not carry the Cre-recombinase allele or were 
not homozygous for the Ext1e2fl allele did show any sign of osteochondroma 
development (Table 1 and Jones et al., 2010).  
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Table 1. Frequency of osteochondromas development after doxycycline induction. 
 
4.2.3 Murine osteochondromas resemble the human phenotype 
As already shown by morphological staining mutants at eight weeks of age have 
developed exostoses of considerable size, that can easily be depicted at the side 
of the femur (Fig. 20). To investigate if, as in human patients, osteochondromas 
are formed on all endochondral bones skeletal preparation were stained with 
Alizarin red, which detects calcium deposits of the mineralized matrix. In induced 
Col2-rtTA-Cre;Ext1e2fl/e2fl animals at the age of eight weeks, osteochondromas are 
not restricted to the extremities, but developed on all endochondral bones 
including the vertebrae, (Fig.21 C, D, C1, D1) as well as the pelvic bone (Fig.21 A, 
B, A1, B1), thus mimicking the human phenotype. Moreover, similar as in human 
patients, bones severely affected by osteochondromas are frequently reduced in 
size compared to control bones (Fig. 21 C, D)  
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Figure 21. Doxycycline treated Col2-rtTA-Cre;Ext1e2fl/e2fl  mice show exostoses at 
many sites of the endochondral skeleton. Alizarin red staining of the pelvic bone (A, B, 
A1, B1) and vertebrae (C, D, C1, D1). Col2-rtTA-Cre;Ext1e2fl/e2fl pelvic bone (A1 higher 
magnification of A) develop osteochondromas. Furthermore, mutant vertebrae (C1 higher 
magnification of C) are shorter compared to the control (D1 higher magnification of D) and 
show several exostoses (blue arrows in C1). 
To test if Col2-rtTA-Cre;Ext1e2fl/e2fl osteochondromas display a similar cellular 
organization as the human tumors, in situ hybridization with markers for different 
chondrocyte populations were performed (Fig. 22 B-E). Morphologically human 
osteochondromas have a bony stalk in contact with the cortical bone and the bone 
marrow and are covered by a cartilage cap at the outside. The organization of 
chondrocyte populations in the cartilage cap resembles the organization of the 
growth plate (Wicklund et al., 1995; Gordon et al., 1981; Peterson, 1989). In situ 
hybridization revealed that Col2-rtTA-Cre;Ext1e2fl/e2fl osteochondromas cells 
distribute similar as in human osteochondromas. The chondrocytes in murine 
osteochondromas express the typical differentiation markers of the embryonic 
growth plate: ColX, Ihh, Ptch1, and Col2. Hypertrophic, ColX-expressing 
chondrocytes are in contact with the mineralized bone, adjacent to prehypertrophic 
Ihh-expressing and columnar Ptch1-expressing chondrocytes. These are 
surrounded by proliferating Col2-expressing chondrocytes.  
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Figure 22. The cellular organization of Col2-rtTA-Cre;Ext1e2fl/e2fl osteochondroma 
resembles a growth plate. Parallel sections of 8-week-old mice were stained with 
Toluidine blue (A and A1) and hybridized with antisense riboprobes for Col2 (B), ColX (C), 
Ihh (E), and Ptch1 (F). In situ hybridization demonstrates that osteochondroma 
chondrocytes mimic the organization of the physis, with Col2 expressing proliferating 
chondrocytes followed by Ihh- and ColX-expressing hypertrophic chondrocytes (F). 
Similar to the growth plate Ptch1 is expressed in proliferating chondrocytes, flanking the 
Ihh expression domain. (Fig. A shows higher magnification of boxed areas in A1). 
Magnification 50X (A); 100X (A1, B-E). 
4.2.4 A physeal proliferative chondrocyte is the cellular origin of 
osteochondromas 
To understand the initiation of osteochondroma formation and to identify the cell 
type in which they originate, the relative position of the tumor to the growth plate 
was carefully investigated. Femurs of Col2-rtTA-Cre;Ext1e2fl/e2fl mice at different 
ages were compared (4, 5, 6 and 8 weeks old mice) starting with 8 weeks old mice 
(Fig. 23). At this stage mice have reached their sexual maturity, comparable to the 
end of puberty in humans. Osteochondromas usually stop growing at the end of 
puberty when the growth plate itself closes and cells cease to proliferate (Legeai-
Mallet et al., 1997; Schmale et al., 1994; Wicklund et al., 1995; Gordon et al., 
1981; Peterson, 1989). Morphological staining revealed that 8 weeks old Col2-rtTA-
Cre;Ext1e2fl/e2fl mutants display massive exostoses at the distal end of the femur 
which occasionally are still in contact with the proliferative zone of the growth plate 
(Fig. 23D). In order to define at which stage osteochondroma formation is initiated, 
femurs of younger mice, between 4 and 6 weeks of age were analyzed. 4, 5 and 6 
weeks old Col2-rtTA-Cre;Ext1e2fl/e2fl  mice revealed smaller osteochondromas, 
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which are less differentiated than in the 8 weeks old mutants. In most cases, 
especially in the younger tumors, the clones consist exclusively of chondrocytes 
(Fig. 23 B, C), which are surrounded by a highly developed extracellular matrix 
(Fig. 23 C1). 
 
Figure 23. Osteochondromas develop from growth plate chondrocytes into massive 
tumors at femur epiphyses. Hematoxyline/Eosin staining of femur sections at 4, 5, 6 and 
8 weeks of age (A to D). In 4 weeks old Col2-rtTA-Cre;Ext1e2fl/e2fl mice few cells disrupt the 
growth plate organization (A, A1 higher magnification of the red box in A), to proliferate 
and expand at the side of the femur growth plate (B, C, D), developing into massive, 
differentiated osteochondromas in 8 weeks old mutants. Higher magnification of 
osteochondromas from 6 weeks old mice (C1 and C) show clustered organization of 
chondrocytes. Magnification 100X (A, B, C, D) and 20X (A1, C1). 
Interestingly at 4 weeks of age Col2-rtTA-Cre;Ext1e2fl/e2fl mice show very small 
clones of chondrocytes, located at the upper side of the growth plate where it is 
connected to the articular cartilage (Fig. 23A) that are clearly separated from the 
growth plate by the extracellular matrix To confirm the morphological observation 
that these early osteochondromas consist of chondrocytes I analyzed the 
expression of chondrocyte markers (Fig. 24). In situ hybridization revealed that 
these early osteochondroma cells express Col2 and Ucma, a matrix protein typical 
for early proliferating chondrocytes (Tagariello et al, 2008) (Fig.24 B, D). The same 
cells lacked of ColX and Ihh expression (Fig.24 C, E), demonstrating that in 4 
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week old Col2-rtTA-Cre;Ext1e2fl/e2fl mice the osteochondromas consist of early 
proliferative chondrocytes which have not differentiated into pre– or hypertrophic 
chondrocytes, yet. In summary gene expression analyses confirmed the 
morphological observations that a chondrocyte is likely the cellular origin of 
osteochondromas in Col2-rtTA-Cre;Ext1e2fl/e2fl mice. The location of these clones in 
or on close proximity to the growth plate strongly indicates that osteochondromas 
in Col2-rtTA-Cre;Ext1e2fl/e2fl  mice develop from physeal chondrocytes, which 
proliferates and further differentiates into a more complex structure resembling the 
human osteochondromas. 
 
Figure 24. Gene expression analyses confirm a growth plate chondrocyte as 
cellular origin of osteochondromas in Col2-rtTA-Cre;Ext1e2fl/e2fl mice. Parallel sections 
of distal femurs from 4-week-old mice were stained with Toluidine blue (A and A1) and 
hybridized with antisense riboprobes for Col2 (B), ColX (C), Ucma (E), and Ihh (F). These 
early osteochondromas express no Ihh, or ColX, but strongly express Col2 and UCMA, 
markers for early proliferating chondrocytes. A1 shows higher magnification of boxed area 
in A. Magnification 100X (A, B-E); 200X (A1) 
4.2.5 Loss of heterozygosity is required for development of 
osteochondromas 
One controversially discussed question is the allelic status of the human 
osteochondromas. It has not been clarified yet if haploinsufficiency of EXT genes 
is sufficient to disturb cell signaling in the growth plate or a complete loss of 
function is necessary. To further investigate the etiology of MO syndrome, clones 
of 1 to 10 mutant cells were isolated from sections of Col2-rtTA-Cre;Ext1e2fl/e2fl 
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osteochondromas at different developmental stages by laser capture 
microdissection (LCM) (Fig. 25 A). In order to amplify small amounts of DNA 
representing 1-10 genomes (8pg DNA/genome) nested primer pairs were 
designed detecting the wt and the inverted allele respectively. To amplify a single 
genome the first amplification round was performed in a single reaction using one 
forward primer detecting both alleles and two reverse primers, for the wt and the 
inverted allele respectively. As the difference in size between the two nested PCR 
products was too small to be detected on an agarose gel (54 base pairs) the 
second amplification round was performed in separated reactions (Fig. 25 B). 
128 out of 183 clones analyzed, about 70%, were not successfully amplified by 
PCR. This failure rate matches the technical success rate of other studies in which 
LCM analyses were performed on paraformaldehyde-fixed, paraffin embedded 
tissues (Becker et al., 1997; Ohno et al., 1997). The results of our genotyping 
analyses revealed that of the remaining 55 successfully analyzed clones, 38 were 
homozygous for the inverted allele Ext1e2flinv/e2flinv, 14 were homozygous for the wt 
allele (Ext1e2fl/e2fl) and three were heterozygous (Ext1e2fl/e2flinv.) indicating that in our 
mouse model osteochondroma cells carried all possible genomic rearrangements 
of the Ext1 transgene. Approximatively 70% of the clones of osteochondromas 
tissue carried a homozygous mutation (Fig. 25 C). This result supports the 
hypothesis that loss of heterozygosity happens in a small cluster of cells, which 
eventually proliferate and expand, possibly including wt cells into its structure. 
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Figure 25. Osteochondromas chondrocytes are mostly homozygous for the 
inversion of exon 2 of Ext1. (A) Immunohistochemistry with 10E4 antibody on 
osteochondroma of a 6-week-old Col2-tTA-Cre;Ext1e2fl/e2fl  shows that loss of HS 
correlated with homozygosity for the inverted allele in parallel sections (red-encircled 
clones in A2, red arrows in A1). HS-positive chondrocytes demonstrated the Ext1e2fl/e2fl 
(yellow-encircled clones in A2, yellow arrows in A1) genotype. Nested PCR on cell lysate 
after laser microdissection (LCM) was used to identify forward or reverse orientation of 
exon 2 (B). Genomic DNA was used as positive controls for the wt and the inverted allele 
as indicated. Water control was used to confirm lack of contaminations (H2O). The 
distribution of 55 LCM-identified clone genotypes from osteochondroma chondrocytes 
demonstrates a strong majority of Ext1e2flinv/e2flinv genotypes at all ages (C). Bar in 
A=300µm; Bar in A1-A2=150µm.  
4.2.6 HS staining confirms loss of heterozygosity in Col2-tTA-
Cre;Ext1e2fl/e2fl osteochondromas 
To further confirm the spatial distribution of genotypes within the osteochondromas 
parallel sections were analyzed by LCM genotyping and 10E4 
immunohistochemistry (Fig. 25 A, 26). Femurs of 8 and 4 old weeks mice (Fig. 26 
A and B) show a strong HS staining in growth plate chondrocytes, while 
osteochondromas cells are depleted of HS synthesis. No HS is detected on 6 out 
of 10 osteochondromas and 4 osteochondromas display a minority of clones still 
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producing small amounts of HS. Genetic analyses confirm that HS-negative areas 
consistently were Ext1e2flinv/e2flinv and that osteochondromas containing Ext1e2fl/e2fl 
cells displayed small discrete regions of HS synthesis. The observation that most 
of the osteochondroma tissue is depleted of HS (Fig. 26) support the 
morphological observation that osteochondromas develop from a growth plate 
chondrocyte, which is not able to produce HS, and develop into a structure mostly 
composed of cells that do not produce any functional Ext1 protein.  
 
 
Figure 26 HS staining of osteochondromas supports loss of heterozygosity theory. 
Parallel sections of 8 and 4 week-old mice were analyzed by immunohistochemistry using 
the 10E4 antibody and counterstained with Methyl Green (A and B). HS staining 
demonstrates normal HS distribution in physeal chondrocytes (A and B, right Insets) but 
absence of HS in osteochondroma chondrocytes (A1 and B1). Magnification 100X (A and 
B); 200X (A1 and B1). 
As reported previously, HS plays an important role in chondrocyte differentiation 
(Koziel et al., 2004). To investigate whether a chondrocytes lacking HS production 
can still differentiate into different chondrocyte subtypes, the distribution of HS on 
sections of Ext1Gt/Gt mice was analyzed by immunohistochemistry using the 10E4 
and HepSS1 antibodies, which recognize different patterns of GlcNAc or GlcNS 
sequences. Wt mice show a strong staining for both epitopes in the mesenchymal 
tissue surrounding the cartilage anlagen, in the carpal bones and in proliferating 
and hypertrophic chondrocytes of the skeletal elements (Fig.27 D and F). Ext1Gt/Gt 
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mutants show severely reduced 10E4 staining (Fig.27 C) in all chondrocytes, while 
strong HepSS1 staining is detectable in proliferating chondrocytes (Fig. 27 E). 
Ext1Gt/Gt mutants still produce a 20% of the amount of wt HS and the distribution of 
the two different epitopes is consistent with previous biochemical analyses 
(Yamada et al. 2004). The epitope recognized by the HepSS1 antibody was 
shown to be represented in Ext1Gt/Gt mutants in an amount comparable to wt mice, 
while the sequence that reacts with the 10E4 antibody is less represented in 
Ext1Gt/Gt mutants than in wt embryos. In contrast to Ext1Gt/Gt immunohistochemistry 
for 10E4 and HepSS1 on parallel sections of Col2-tTA-Cre;Ext1e2fl/e2fl  femurs 
reveals that osteochondroma cells show a reduced staining for both antibodies 
further confirming a complete loss of HS synthesis in osteochondromas (Fig. 27 A 
and B). 
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Figure 27. Ext1Gt/Gt mutants show different HS staining patterns for different 
epitopes, while osteochondromas lack HS. 10E4 and HepSS1 immunohistochemistry 
was carried out on E16.5 Ext1Gt/Gt mutant (A and C), control forelimbs (B and D) and 
osteochondromas (E and F). Ext1Gt/+ show strong staining with both antibodies in 
proliferating and hypertrophic chondrocytes and in carpal bones (B, D). Ext1Gt/Gt mutants 
show severely reduced 10E4 staining (A), compared to wt (B) but are positive for HepSS1 
staining (C). In osteochondroma tissue no HS could be detected with either antibodies (E 
and F). Magnification 200X (A and B), 100X (C-F). 
 
4.2.7 Col2-tTA-Cre;Ext1e2fl/e2fl mice display signs of early 
osteoarthritis. 
Osteoarthritis (OA) is a degenerative joint disease characterized by loss of 
proteoglycans in the articular surface of the bones, which affects about 14% of MO 
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human patients (Wicklund et al., 1995). To investigate if Col2-tTA-Cre;Ext1e2fl/e2fl 
mice develop signs of proteoglycan loss, section of knee joints were stained with 
Safranin O and Toluidine blue. Safranin O uniformly stains the articular surface 
(Fig. 28B) of wt mice at 8 weeks of age. In contrast, mutant knee joints at the 
same age show an increased number of chondrocytes with lacunae and irregular 
proteoglycan distribution (Fig. 28A, yellow arrows). In addition many cells in the 
articular surface appear to be hypertrophic. In situ hybridization revealed that in wt 
mice ColX expression is restricted to hypertrophic chondrocytes in the growth 
plate (Fig. 28D, yellow arrow) while strong expression of ColX in both, the growth 
plate and in the articular region, (Fig. 28C, yellow arrows) can be detected in Col2-
tTA-Cre;Ext1e2fl/e2fl mice (Fig. 28E, F, yellow arrows). Since expression of ColX in 
the articular chondrocytes belongs to the symptoms of early OA, older mice were 
analyzed in order to investigate the progression of OA during aging. 
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Figure 28. Col2-tTA-Cre;Ext1e2fl/e2fl joints display symptoms of early osteoarthritis. 
Safranin O (A, B) staining reveals chondrocytes with atypical morphology in the articular 
surface and irregular proteoglycan distribution in 8 weeks old Col2-tTA-Cre;Ext1e2fl/e2fl mice 
(A, yellow arrows) while control mice show uniformly distributed proteoglycan staining (B). 
In situ hybridization (C-F) confirms that chondrocytes turn hypertrophic in the mutant, 
shown by strong ColX expression in the articular cartilage (C, yellow arrows). The control 
shows normal ColX expression in the growth plate, but not in the articular surface (D, 
yellow arrow). Higher magnification confirms that ColX expression is consistent with 
hypertrophic morphology (E, F yellow arrows). (T: tibia; F: femur). Magnification 100X (C 
and D); 200X (A, B, E and F).  
Mice were sacrificed at 3, 6 and 8 months of age. In wt mice chondrocytes of the 
articular surface are distributed in three typical zones, superficial (SZ), middle (MZ) 
and deep zone (DZ), and a strong proteoglycan staining is present in all layers. 
Cells in the superficial zone are small, flattened and orientated parallel to the 
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articular surface. Cells of the middle zone are rounder and do not show a specific 
orientation relative to the surface. Deep zone cells are organized in groups of 
three or more cells, which arrange in columns perpendicular to the surface and are 
surrounded by an extensive pericellular matrix (Tyyni and Karlsson 2000; Grogan 
et al., 2009; Youn et al., 2006). In the mutant joints distribution and orientation of 
cells through the three zones is disturbed. Articular cartilage in Col2-tTA-
Cre;Ext1e2fl/e2fl mutant joints display loss of cellularity and the chondrocytes of the 
superficial zone fail to align parallel to the joint surface (Fig. 29 A, B). Moreover, 
big lacunae are detectable in the articular surface, most likely generated after 
hypertrophic chondrocytes undergo apoptosis (Fig 29 A, A1, red arrows). 
Enzymatic degradation of aggrecan, one of the main components of the articular 
ECM by Mmps, resulting in the generation of the epitope VDIPEN, is one of the 
symptoms of OA. In order to confirm that loss of proteoglycan staining was due to 
proteolytic degradation of aggrecan VDIPEN immunohistochemistry was 
performed. While healthy knees do not react with the VDIPEN antibody, the 
VDIPEN epitope could clearly be detected in regions that show loss of 
proteoglycan staining (Fig. 29C, D red arrows) confirming that Col2-rtTA-
Cre;Ext1e2fl/e2fl mice spontaneously develop OA. Interestingly, the cartilage cap of 
osteochondromas is also strongly positive for VDIPEN staining (Fig. 28E, F, red 
arrows), suggesting that Mmp activation could be associated to Ext1 loss of 
function. 
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Figure 29. Col2-tTA-Cre;Ext1e2fl/e2fl develop osteoarthritis during aging. Safranin O (A, 
B) and Toluidine Blue (A1) staining on 3 months old Col2-tTA-Cre;Ext1e2fl/e2fl knees show a 
non-homogeneous distribution of proteoglycan in the articular cartilage. Big lacunae can 
be detected (A, A1 red arrows), in the mutant articular surface. VDIPEN 
immunohistochemistry (C, E) and Toluidine Blue staining (D, F, red arrows) of 8 months 
old Col2-tTA-Cre;Ext1e2fl/e2fl mice show that cartilage loss is due to Mmp13-mediated 
proteolytic degradation of aggrecan. Strong VDIPEN staining can be detected in the 
cartilage cap of osteochondromas (E, red arrow). (T: tibia; F: femur). Magnification 200X.  
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5. Discussion 
5.1 Role of HS during the ossification process 
Multiple osteochondroma (MO) syndrome, previously known as hereditary multiple 
exostoses (HME) syndrome, is a human autosomal dominant disorder 
characterized from the formation of benign bone tumors at the metaphysis of 
endochondral bones.  
MO has been associated with loss of function mutations in EXT genes, with a 
more severe phenotype associated with EXT1 mutations rather than EXT2 
(Lüdecke et al., 1995; Porter et al., 2004; Wuyts et al., 1995). EXT1 and EXT2 
encode glycosysltransferases, which are essential for heparan sulfate (HS) 
synthesis.  
Many theories about the etiology of osteochondromas have been suggested and 
two vital questions remained open. First, which cell type is the origin of MO? The 
two principal suspects are an epiphyseal plate chondrocyte or an osteoblastic cell 
from the adjacent perichondrium. Second, which is the genetic event that initiates 
the development of osteochondromas? Is haploinsufficiency of EXT genes 
followed by disturbed cell signaling in the growth plate or is a complete loss of 
function due to loss of heterozygosity in somatic cells necessary? 
5.1.1 HS has no direct influence on osteoblast and osteoclast 
differentiation in Ext1Gt/Gt mice 
In order to understand the mechanisms underlying osteochondroma formation, 
several mouse models have been generated so far. Homozygous deletion of Ext1 
and Ext2 genes in mice, which are deficient for HS, die prior to bone formation, 
thus precluding analysis of MO (Lin et al., 2000; Stickens et al., 2005). Only Ext2+/- 
mice develop small exostoses at the costochondral cartilage of the ribs with low 
frequency (28%; Stickens et al., 2005). 
In another mouse model, the Ext1Gt/Gt mutants produce 20% of the wild type (wt) 
HS content and survive until E16.5 (Koziel et al., 2004; Yamada et al., 2004). In 
Ext1Gt/Gt HS has been shown to play a key role in chondrocyte differentiation, 
regulating the distribution of the morphogen Ihh along the longitudinal axis of 
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cartilage anlagen.  
Ihh regulates chondrocytes proliferation and differentiation, interacting in a 
negative feedback loop with the secreted growth factor Parathyroid hormone 
(PTH) related protein (PTHrP). Ihh is produced by prehypertrophic and early 
hypertrophic chondrocytes and signals through its receptor Patched-1 (Ptch1) to 
upregulate PTHrP in the distal periarticular chondrocytes. PTHrP signals back to 
its receptor, the shared PTH/PTHrP receptor (PPR), expressed by proliferating 
and prehypertrophic chondrocytes, thereby inhibiting the differentiation of 
proliferating cells into prehypertrophic chondrocytes. HS negatively regulates the 
propagation of Ihh in the cartilage anlagen. Early stages of chondrocytes 
differentiation are perturbed in Ext1Gt/Gt mice, as Ihh protein can travel further 
upregulating PTHrP in the distal chondrocytes. PTHrP in turn delays the onset of 
hypertrophic differentiation (Koziel et al., 2004). 
Ihh also regulates osteoblast differentiation and vascular invasion of the cartilage 
anlagen. It has been shown that Ihh deficient mice exhibit severe defects in 
cartilage vascularization and osteoblast development during endochondral 
ossification (St-Jacques et al., 1999). Moreover, targeted deletion of Smoothened 
(Smon/n), which results in ablation of all Hh signals, reveals that in these mice 
formation of normal bone collar and development of the primary spongiosa was 
abolished (Long et al., 2003). While ablation of Ihh signaling pathway inhibits 
osteoblast differentiation and blood vessel formation, its activation can accelerate 
ossification and induce vascularization (Kinto et al., 1997). Furthermore, activation 
of signaling downstream of Ihh is sufficient to induce vascularization of the 
hypertrophic cartilage in vivo in the absence of Ihh (Joeng and Long, 2009).  
Preliminary investigations revealed that the ossification process could be disturbed 
in the Ext1Gt/Gt mutant skeletal elements. Therefore, the effect of HS on osteoblast 
and osteoclast differentiation was investigated in Ext1Gt/Gt mutants. In situ 
hybridization analyses show that cartilage matrix resorption and osteoblast 
differentiation are both delayed compared to wt embryos but both are taking place 
in the anlagen of E16.5 Ext1Gt/Gt mutants, and seem to be normal in relation to 
hypertrophic differentiation (Fig. 10). Gene expression analysis revealed delayed 
osteoblast and osteoclast differentiation in Ext1Gt/Gt mutants as a consequence of 
delayed chondrocyte differentiation (Koziel et al, 2004), but not as a direct effect of 
the reduced amount of HS (Fig. 10 and 11). HS might thus have different effects 
on the distribution of Ihh in chondrocytes and in the surrounding periosteum. 
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5.1.2 HS regulates vascularization by influencing the distribution of 
VEGF-A  
When chondrocytes turn hypertrophic they start to produce a calcified extracellular 
matrix (ECM) and angiogenic stimulators, such as VEGF-A, thereby inducing the 
first vessel invasion of the cartilage anlagen. The vasculature in turn supplies the 
bone template with cells belonging to the osteoblast and osteoclast lineage 
necessary for deposition of a mineralized bone matrix and resorption of the 
chondrogenic matrix.  
The fundamental role of VEGF-A signaling during endochondral ossification has 
been confirmed by experiments where disturbed blood vessel formation impaired 
correct development of the growth plate. It has been shown that VEGF-A is 
produced by hypertrophic chondrocytes and that inhibition of VEGF-A by 
administration of soluble Flt1 impaired growth plate vascular invasion (Gerber et 
al., 1999). Defects in blood vessel formation have also been associated to reduced 
release of VEGF from the hypertrophic cartilage matrix which is mediated by 
Mmps. Mmp9 deficient mice show a massive and transient enlargement of the 
hypertrophic zone, due to delay in chondrocyte apoptosis, capillary invasion and 
ossification (Vu et al., 1998). This phenotype is similar to that generated by 
inhibition or conditional deletion of VEGF-A, suggesting a possible role of Mmp9 
for VEGF-A release (Gerber et al., 1999; Haigh et al., 2000). Furthermore, VEGF-
A has been suggested to have a direct role in osteoclastogenesis and therefore in 
cartilage resorption. In vitro experiments show that VEGF-A can directly enhance 
the resorption activity and survival of mature osteoclasts (Nakagawa et al., 2000). 
Recombinant VEGF-A can induce osteoclast recruitment, survival and activity in a 
mouse model for osteopetrosis, a rare inherited disorder, characterized by harder 
and denser bones (Niida at al., 1999). Osteoclasts express Flt-1 and Vegf-A from 
hypertrophic chondrocytes has been shown to be a chemoattractant for 
osteoclasts invading the developing bone (Blavier and Delaisse, 1995; Engsig et 
al., 2000; Henriksen et al., 2003). These observations correspond to the 
phenotype of Ext1Gt/Gt mutant mice. In these mice mineralization occurs at E16.5, 
concomitantly to hypertrophic differentiation (Fig. 10 A, E and 11 E), while ColX 
matrix is not degraded, although Mmp13 is expressed (Fig. 10 C). Also osteoclasts 
invasion is inhibited at E16.5 in Ext1Gt/Gt mutant anlagen (Fig.11 K). Ext1Gt/Gt mice 
show an edematous aspect and have severe defects in heart formation, indicating 
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defects in vascular development. As cartilage resorption and osteoclasts invasion 
are disturbed similar to phenotype in which VEGF signaling is impaired I 
investigated if blood vessels development is disturbed in Ext1Gt/Gt mice. In these 
mice, distribution of endothelial cells in E14.5 and E16.5 forelimbs is disorganized 
(Fig.12). Ext1Gt/Gt mice show delayed expression of vascularization markers, which 
is normal in relation to hypertrophic differentiation, as for ossification markers, 
therefore most likely due to delayed chondrocyte differentiation (Fig. 13 and 14) 
(Koziel et al., 2004). HS mediates binding of VEGF-A to its receptors, thereby 
activating the signaling pathways which promote rearranging and development of 
the blood vessel net. In vitro experiments of embryonic stem cell cultures chimeric 
for either HS production or VEGFR2 synthesis reveal that HS can mediate 
activation of VEGF-A signaling in trans in endothelial cells (Jakobsson et al., 
2006). In zebrafish, knock-down of Perlecan, which belongs to the family of HS, 
caused an abnormal increase and redistribution of VEGF-A, suggesting a role for 
HS in generating a VEGF gradient and providing an instructive signal for 
endothelial cells during angiogenesis (Zoeller et al., 2009). Similarly, a VEGF-A 
splice variant with low affinity for HS has been shown to activate VEGFR2 in a 
weak and transient way, while VEGF-A165 induced a strong and sustained 
response (Cebe-Suarez et al., 2006).  
As gene expression of vascularization markers is normal in relation to hypertrophic 
differentiation but morphological analyses revealed that vascular invasion is 
disturbed in Ext1Gt/Gt mutant I analyzed if reduced amounts of HS can be 
responsible for defects in the VEGF-A protein distribution. In vitro Ext1Gt/Gt 
chondrocyte cultures, producing reduced levels of HS, attract endothelial cells 
more efficiently than wt cultures (Fig. 15). Since the level of Vegf-A transcript is 
similar in Ext1Gt/Gt mutant and control cultures, the increased migration of 
endothelial cells towards the Ext1Gt/Gt mutant culture does not seem to depend on 
Vegf-A upregulation (Fig. 16). Instead, these results indicates a function for HS in 
regulating VEGF-A protein distribution, as the reduced amount of HS chains 
decorating the surface of Ext1Gt/Gt chondrocytes might be responsible for an 
increased release of VEGF-A protein from the cell surface. This results in 
enhanced levels of freely diffusible protein in the medium, which is more 
accessible to endothelial cells. 
In vivo, this would not only perturb blood vessel invasion but also reception of the 
VEGF-A signal by osteoclasts from the surrounding perichondrium. Hence, these 
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cells would not invade the primary ossification center, thereby impairing resorption 
of the cartilage matrix. This hypothesis fits to the phenotype observed in this study. 
Ext1Gt/Gt chondrocytes are able to express Vegf-A (Fig. 13 C and 14 C), but 
endothelial cells are disorganized and not able to invade the primary ossification 
center (Fig. 12 A and C). Since HS regulates VEGF-A distribution as well as 
binding of VEGF-A to its receptors, both protein distribution and activation of the 
vascularization signaling pathway at the site of the primary ossification center 
might be disturbed in Ext1Gt/Gt mutants. This hypothesis is in agreement with the 
phenotype of Ext1Gt/Gt mutants, where blood vessel formation and osteoclast 
invasion are both impaired (Fig. 11 and 12), but gene expression of osteogenic 
and vascularization markers is not considerably delayed, as revealed by in situ 
hybridization (Fig.10, 13 and 14). Western blot analysis of VEGF-A release as well 
as immunohistochemistry to reveal the activation status of VEGF receptors will be 
necessary to elucidate how HS influences vascularization of the growth plate. 
5.2 Development of osteochondromas 
5.2.1 Strategy to model loss of heterozygosity and disruption of 
Ext1 function  
In the past few years, the MO syndrome has been intensively studied in the 
attempt to understand how osteochondromas arise. Data collected from human 
patients suggested different controversial hypotheses. The hypothesis that 
osteochondromas originate from the chondrocyte lineage is supported by animal 
studies in which transplantation of a growth plate at a 90° angle to the longitudinal 
axis of the normal growth plate can generate exostoses (D´ambrosia et al., 1968). 
Furthermore, in human patients a second somatic mutation was found only in the 
cartilaginous cap indicating a chondrocyte as the origin of MO (Bovée et al., 1999, 
Hameetman et al., 2007). Additionally these studies support the hypothesis that 
loss of heterozygosity (LOH) of the EXT1 and EXT2 genes is essential for MO 
formation, defining them as tumor suppressor genes (Bovée et al., 1999; 
Hameetman et al., 2007). In this scenario human patients are in a heterozygous 
state and clonal expansion of cells carrying a second somatic mutation would lead 
to the generation of exostoses. However, a second mutation could not be 
identified in all human osteochondromas. Cells with only one functional EXT1 or 
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EXT2 allele might not be 100% efficient in HS production, thereby causing 
misregulation of HS-dependent cell signaling (Bovée et al., 1999; Hameetman et 
al., 2007).  
Finally, the observation that late stage human osteochondromas are usually in 
continuity with the cortical and medullary bone is indicating possible defects in 
bone collar differentiation. Moreover, animal experiments have shown that injury of 
the perichondrial groove of Ranvier leads to formation of solitary osteochondromas 
(Delgado et al., 1987).  
As neither Ext1+/-, Ext2+/- or Ext1Gt/+ mice develop osteochondromas and Ext1Gt/Gt 
mice die around E16.5, not allowing to study later stages of endochondral bone 
development and more importantly formation of osteochondromas, I analyzed a 
mouse model that carries a conditionally targeted Ext1 allele either in the wild type 
(Ext1e2fl/e2fl) or in the inverted orientation (Ext1e2flinv/e2flinv). Homozygous mice for the 
inverted allele showed the same phenotype as the null allele, with extraembryonic 
and embryonic structures morphologically not distinguishable. More importantly, 
Ext1e2flinv/e2flinv tissue did not produce any HS, as shown by immunohistochemistry. 
The analysis of these mice is useful as a model to induce somatic Ext1 loss of 
function to study osteochondroma development. 
To mimic the events that are suspected to generate exostoses I crossed Ext1e2fl/e2fl 
mice into a mouse line, which expresses Cre recombinase under the Col2 
promoter, active in proliferating chondrocytes. 
5.2.2 Loss of heterozygosity in a chondrocyte is generating 
osteochondromas 
5.2.2.1 Osteochondromas generate by loss of heterozygosity 
Which the first event is that lead to generate osteochondromas has been for a long 
time disputed. Osteochondromas have been first thought to be the consequence 
of skeletal dysplasia. After the founding that osteochondromas development is 
linked to mutation in EXT1 and EXT2 genes (Ahn et al., 1995; Bovée et al., 1999; 
Lüdecke et al., 1997; Wuyts et al., 1998, Wuyts and Van Hul, 2000) it is now 
generally accepted that exostoses are neoplastic. As mutations are autosomal 
dominant inherited, the EXT genes belong to the category of tumor suppressor 
genes. Although loss of heterozigozity has been demonstrated in the cartilage cap 
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of osteochondromas of MO patients (Bovée et al, 1999, Hameetman et al., 2007), 
this second mutation could not be detected in all MO patients, raising the question 
for the initial event in the development of the disease. Several evidences I 
collected during my analyses suggested that LOH is necessary for the 
development of osteochondromas. First, Col2-rtTA-Cre;Ext1e2fl/e2fl mice developed 
osteochondromas with 100% penetrance when induced with doxycycline, while 
none of the other genotypes that were induced with doxycycline showed 
exostoses, including Col2-rtTA-Cre;Ext1e2fl/+. This supports the theory that Ext1 
haploinsufficiency is not enough to generate osteochondromas and that a second 
mutation is necessary (Bovée et al., 1999; Hameetman et al., 2007). After 
induction at 8 weeks of age mice show big osteochondromas, resembling the 
human phenotype in cellular organization (Fig. 20-22). Late stage 
osteochondromas are still in contact with the cortical bone and the bone marrow 
and chondrocytes are organized in different population with hypertrophic and 
prehypertrophic chondrocytes surrounded by a cartilage cap, as confirmed by 
morphological analyses and in situ hybridization (Fig. 22). Genotyping analyses of 
small chondrocyte clones isolated by laser microdissection revealed that at least 
70% of the cells isolated from osteochondromas were homozygous for the 
inverted allele (Fig. 25). Furthermore, most of the osteochondromas did not 
synthesize HS. Immunohistochemistry revealed that when HS was produced, it 
was confined to discrete regions within the tumor tissue (Fig. 25-27). A similarly 
abnormal and decreased distribution of HS was observed in human 
osteochondromas (Hecht et al., 2002; Trebicz-Geffen et al., 2008). Interestingly, 
genotyping analyses revealed that osteochondromas of Col2-rtTA-Cre;Ext1e2fl/e2fl 
mice diplay a mixed genotype similar to that observed in humans (Fig. 25). This 
could be explained by the fact that wt cells can be included in the 
osteochondromas during its growth and therefore cells isolated from late stage 
human osteochondromas diplay a mixed genotype. However, osteochondromas of 
Col2-rtTA-Cre;Ext1e2fl/e2fl mice diplay also a mixed genotype but the results 
presented in this study strongly indicate that osteochondromas develop by clonal 
expansion of a small cluster of chondrocytes, which are deficient for HS (Fig. 26). 
As I have shown that lack of HS can be correlated with loss of function of both 
alleles of Ext1 (Fig. 25) a plausible conclusion is that LOH in a small clone of 
chondrocytes is the initial event for generation of osteochondromas. 
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5.2.2.2 A chondrocyte is the cell of origin of osteochondromas 
As for the cellular origin of MO at least two different cell types have been proposed 
to be the first to mutate. Both chondrocyte or osteoblast progenitor cells have been 
suggested to be eligible candidates (Bovée et al., 1999; D´ambrosia et al., 1968; 
Delgado et al., 1987; Hameetman et al., 2007). To induce generation of 
osteochondromas Ext1e2fl/e2fl mice were crossed to an inducible Cre recombinase 
line, which expression is driven under the Col2 promoter. The Col2 promoter has 
previously been shown to drive expression in both chondrocytes and cells of the 
perichondrium/periosteum embryonically (Long et al., 2001). Therefore a recent 
study analyzed and compared the activity of inducible Cre recombinase under the 
Col2 promoter (Col2-rtTA-Cre) and the Osterix promoter (Osx-CreERT) (Maes et 
al., 2007), a transcriptional factor essential for osteoblast differentiation and bone 
formation (Nakashima et al., 2002). Mice carrying either of these two Cre lines 
were crossed to Rosa26LacZ/+ mice and relative expression were compared by β-
Galactosidase (β-gal) staining. Analyses of knee sections of Col2-rtTA-
Cre;Rosa26LacZ/+ and Osx-CreERT;Rosa26LacZ/+ mice sacrificed at P16, which have 
been induced at P8, revealed that the Col2 promoter drive expression of the allele 
in about 50% of proliferating growth plate chondrocytes and rarely in cells of the 
periosteum and cortical bone and bone marrow, while the Osx promoter revealed 
expression in the osteoblasts of the perichondrium/periosteum and the cortical 
bone and bone marrow. Expression was also detected in hypertrophic 
chondrocytes of the growth plate, but was excluded from the proliferative zone 
(Jones et al., 2010).  
In the present study, I could show that HS has no direct influence on osteoblast 
differentiation (Fig. 10). Moreover, mice in which somatic Ext1 inactivation under 
the Osx promoter were induced demonstrated mild aberrations in hypertrophic 
chondrocytes, but no osteochondromas (Jones et al., 2010). These evidences 
indicate that a cell from the osteoblastic lineage is likely not the origin of MO 
syndrome.  
Observations in Ext2 deficient zebrafish show that HS deficient proliferative 
chondrocytes lose their ability to respond to polarity signals and cannot organize 
into columns (Clement et al., 2008). As previously shown in Ext1Gt/Gt mutants, 
reduced amounts of HS inhibits chondrocyte differentiation and increase the 
proliferative potential (Koziel et al., 2004). Here, I provide evidence that somatic 
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inactivation of Ext1 in proliferative chondrocytes leads to development of 
osteochondromas in mice. Tumors in Col2-rtTA-Cre;Ext1e2fl/e2fl mice arise at the 
side of the growth plate, often still in contact with it, and show a stratified 
distribution of different chondrocytes population similar to the growth plate 
(Fig.22). Morphological observations and gene expression analyses suggest that 
chondrocytes with a early less differentiated character are the cell type to first 
detach from the growth plate, thereby generating osteochondromas (Fig.23 and 
24). Mutant chondrocyte clusters disrupt the columnar organization at the side of 
the growth plate, where this connects to the articular surface (Fig. 24). The clones 
proliferate by clonal expansion (Fig. 23) and differentiate further into columnar, 
prehypertrophic and hypertrophic chondrocytes, forming a growth plate like 
structure as observed in human patients (Fig. 22).  
Further investigations concerning the molecular mechanism perturbed by loss of 
HS are still required. As described previously, HS interacts with Ihh, thereby 
regulating proliferation and differentiation of chondrocytes in the growth plate 
(Koziel et al., 2004). In human osteochondromas, Ihh signaling is activated and is 
probably cell autonomous (Benoist-Lasselin et al., 2006; Hameetman et al., 2006) 
while PTHrP, which is downstream of Ihh, is absent in osteochondroma and 
upregulated upon malignant transformation into osteochondrosarcoma (Bovée et 
al., 2000; Hameetman et al., 2005). Without PTHrP signaling, chondrocyte 
differentiation, hypertrophy, and apoptosis occur after few cycles of proliferation 
(Chung et al., 2001; Kronenberg and Chung, 2001). This would acts against 
formation of osteochondromas but also poor diffusion of Ihh through an Ext 
deficient clone of cells might also result in lack of return signaling of PTHrP. Local 
loss of Ihh expression has been tested in Ihh null/wt chimeric mice, which show 
short and wide skeletal elements but did not develop osteochondromas (Chung et 
al., 2001; Kronenberg and Chung, 2001). However, this mechanism might be 
responsible for the phenotypic shortening of long bones in human patients affected 
by MO, which can also be observed in Ext1Gt/Gt and Col2-rtTA-Cre;Ext1e2fl/e2fl mice. 
Another possibility is that Ihh would influence directly proliferating chondrocytes 
with its mitogenic activity (Chung et al., 2001; Long et al., 2001; St-Jacques et al., 
1999). A reduced amount of HS decorating the cell surface of Ext1 deficient cells 
could lead to a stronger Ihh signaling towards cells neighbouring the mutant 
clones, inducing overproliferation (St-Jacques et al., 1999; Koziel et al., 2004). 
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However, early stage osteochondromas of Col2-rtTA-Cre;Ext1e2fl/e2fl mice do not 
express Ihh (Fig. 24) or Ptch1 (data not shown) indicating that Ihh signaling is not 
active in Ext1 mutant clones. Therefore, the results collected in this study suggest 
that Ihh might not play a role in the early osteochondroma but rather induce 
proliferation in the neighbour chondrocytes, which are surrounding the early stage 
osteochondromas but eventually can be included in late stage osteochondromas, 
as also shown by genotyping analyses (Fig. 25). 
Wnt signaling and TGF-ß signaling have also been shown to be active in the 
majority of osteochondromas (Hameetman et al., 2006). In cell culture 
experiments HS can activate VEGF signaling pathway in trans (Jakobsson et al., 
2006). It is likely that similar activation could work in other signaling pathways as 
well. For example, FGF signaling might also be affected in osteochondromas 
development and could be activated in the same way as VEGF. Cells from the 
perichondrial groove of Ranvier act as a reservoir for osteoblast and mesenchymal 
cell precursors, which express FgfR3, and is responsible for bone growth in width. 
My analyses on Col2-rtTA-Cre;Ext1e2fl/e2fl mice show that early stages 
osteochondromas are situated in proximity to the groove of Ranvier, next to the 
growth plate. Mutant chondrocytes and precursors from the perichondrial groove 
of Ranvier might interact with each other to proliferate and develop into a growth 
plate-like structure, the later stages osteochondromas. Analyses of loss and gain 
of function of FgfR3 in Col2-rtTA-Cre;Ext1e2fl/e2fl mice will help to elucidate if and 
which role cells of the groove of Ranvier might play during MO development. 
5.2.3 Arthritis as complication of osteochondromas 
OA is the most common human joint disorder, characterized by degradation of the 
cartilage matrix associated with increased proteolysis of proteoglycans and 
collagen of the articular surface. This impairs movement of synovial joints by 
causing acute and chronic pain (Koopman, 1997, Resnick, 2002). A typical 
symptom of OA is increased expression and synthesis of degrading enzymes, like 
matrix Mmps and aggrecanases, in synovial tissue and cartilage, with 
accumulation of these in the joint fluids. It has been shown that in mouse models 
in which OA has been induced by injection of interleukine or lysozyme into the 
knee, articular cartilage shows loss of cellularity because chondrocytes become 
hypertrophic and undergo apoptosis. Loss of proteoglycans in the articular 
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cartilage is associated with increased chondrocyte death and Mmp-mediated 
protein degradation, as shown by immunohistochemistry. Induced OA in mice is 
developing fast and, within only three weeks, mice show severe loss of 
proteoglycans in the articular surface (Blaney Davidson et al., 2007; van Lent et 
al., 2005). Nevertheless, these experiments are not suitable to explain which 
molecular mechanisms lead to the spontaneous development of OA. Other mouse 
models, which are either deficient for cartilage matrix proteins or signaling 
molecules, develop OA spontaneously. FgfR3 null mutants show increased ColX 
levels in the articular cartilage associated with a lacunas appearance of 
chondrocytes. At 9 months of age mutant mice display Mmp-mediated degradation 
of cartilage surface (Valverde-Franco et al., 2006). Furthermore, a mouse model 
for Pseudoachondroplasia also develops OA following loss of proteoglycans, but 
only at very late stages (Piróg-Garcia et al., 2007). Mice deficient for Mitogen-
inducible gene 6 (Mig6-/-), a gene involved in stress response, show normal joint 
development at early stages but start to display the first OA symptoms with loss of 
articular proteoglycans at 3 months of age (Zhang et al., 2005).  
In this study a new mose model for OA has been identified. In contrast to the 
models mentioned above, the knee joints of Col2-rtTA-Cre;Ext1e2fl/e2fl mice show 
early symptoms of OA already at 8 weeks of age, as shown by the presence of 
cells expressing high levels of ColX and chondrocytes with lacunae in the articular 
cartilage (Fig. 28). At older stages, the cellularity of the superficial and deep zone 
was reduced in the mutant articular cartilage and degradation of aggrecan could 
by shown by VDIPEN staining in the articular cartilage of Col2-rtTA-Cre;Ext1e2fl/e2fl. 
Interestingly, the staining was also very intense at the surface of osteochondromas 
suggesting that activation of Mmps might be triggered by loss of HS (Fig. 29). This 
assumption is supported by the analysis of hypomorphic Ext1Gt/Gt mice, in which 
the zone of Mmp13 expression is enlarged (Fig. 10). 
Since only few mouse models develop OA spontaneously and only after several 
months, Col2-rtTA-Cre;Ext1e2fl/e2fl mice are an eligible model not only for the 
development of MO, but also to address the molecular mechanisms of early 
stages in osteoarthritis development. As aggrecan is one the most important 
articular cartilage components, induction of somatic Ext1 deletion under the 
aggrecan promoter might provide new insights into the HS dependent regulation of 
OA, and possibly other, bone related diseases. Furthermore, as FGFR3 has a role 
in OA development (Valverde-Franco et al., 2006), another set of experiments 
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might address analysis of both loss and gain of function of FgfR3 in Col2-rtTA-
Cre;Ext1e2fl/e2fl mice. 
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6. Summary  
Multiple osteochondromas (MO) syndrome is an autosomal dominant disease 
characterized by the formation of benign bone tumors (osteochondromas or 
exostoses) at the epiphyses of endochondral bones. Histologically, 
osteochondromas are peduncolate or sessile cartilage capped bony projections, 
usually growing until the end of puberty (Hennekam, 1991). MO has been 
associated to loss of function mutations in EXT genes, with a more severe 
phenotype associated to EXT1 mutations rather than EXT2 (Lüdecke et al., 1995; 
Porter et al., 2004; Wuyts et al., 1995). EXT1 and EXT2 encode for 
glycosyltransferases responsible for elongation of Heparan Sulfate (HS) chain. HS 
are polysaccharides decorating the plasma membrane of all animal cells and a 
major component of the extracellular matrix. They play a key role in mediating the 
activation of different signaling pathways, like FGF and VEGF, and regulation 
spatial distribution of morphogens like Ihh and BMPs. Two fundamental questions 
remain open about osteochondromas development. 
1. Which is the cellular origin of osteochondromas? It has been proposed that the 
first event that leads to development of the disease could happen either in a 
physeal chondrocyte or in a cell of osteoblastic lineage from the adjacent 
perichondrium.  
2. The molecular mechanism responsible for osteochondromas development is 
still unclear. As MO is an autosomal dominant syndrome it might be either that 
haploinsufficiency could be sufficient to induce misregulation of HS-dependent 
signaling pathways, or that loss of heterozygosity is necessary for exostoses to 
develop. In this study different mouse models were analyzed to find the molecular 
function of HS during osteochondromas development. In contrast to Ext1-/- mice 
which die during gastrulation Ext1Gt/Gt mice survive until midgestation. Ext1Gt/Gt 
produce about 20% of HS content compared to wild type. Previous data from 
these mice revealed a general delay in chondrocyte differentiation due to the 
reduced amount of HS (Koziel et al., 2004). In additional to an effect on 
chondrogenesis, loss of HS leads to failure in vascular development. In cell culture 
experiments I identified a defect in the production/release of VEGF-A protein, 
which regulates the correct activation of vascularization. Correlated to the 
perturbed vascularization, osteoclast invasion and bone formation was also 
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delayed in Ext1Gt/Gt mutant.  
As Ext1Gt/Gt die at embryonic stage of development, rendering prohibitive to study 
osteochondromas development I analyzed a conditional mouse model for Ext1 
(Col2-rtTA-Cre;Ext1e2fl/e2fl). In these mice, allelic recombination leads to disruption 
of Ext1 function, similarly to Ext1-/- and Ext2-/- mice. Col2-rtTA-Cre;Ext1e2fl/e2fl mice 
developed osteochondromas at endochondral bones, both in the axial and 
appendicular skeleton. Femurs of Col2-rtTA-Cre;Ext1e2fl/e2fl mutant mice were 
analyzed at different stages (between 4 and 8 weeks old) to observe 
osteochondromas development at the side of the growth plate. At early stages, in 
4 to 6 weeks old mice, osteochondromas are mostly chondrogenic, developing 
from a small chondrocyte cluster into a more complex structure, in which 
chondrocytes have differentiated into different cell population, resembling the 
organization of the growth plate. Cells from osteochondroma tissue were isolated 
by laser microdissection for genetic analyses and the HS amount was analyzed by 
immunohistochemistry.  
In addition Col2-rtTA-Cre;Ext1e2fl/e2fl mice show signs of early osteoarthritis, which 
lead to enzymatic proteoglycan loss as shown by immunohistochemistry. 
 In conclusion my data support the hypothesis that MO syndrome is generated by 
Loss of heterozygosity in a distal chondrocyte of the growth plate, which 
proliferates and differentiates into a structure that resemble the growth plate 
organization. Moreover, HS regulate vascularization of the cartilage by 
modification of VEGF-A protein production or release, which influences in turn 
osteoblast differentiation. 
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7. Zusammenfassung 
Multiples Osteochondrom (MO) ist eine autosomal-dominant vererbte, genetische 
Erkrankung, welche durch epiphysäre, gutartige Knochentumore charakterisiert ist 
(Hennekam, 1991). Bisherige Studien zeigten, dass Mutationen in einem der 
beiden Exostosin Gene EXT1 und EXT2 an der Entstehung von MO beteiligt sind, 
wobei ein stärkerer Phänotyp bei EXT1 Mutationen beschrieben ist (Lüdecke et 
al., 1995; Porter et al., 2004, Wuyts et al., 1995). EXT1 und EXT2 kodieren für 
Glycosyltransferasen, welche für die Synthese von Heparansulfatketten 
verantwortlich sind. Heparansulfate (HS) sind Polysaccharide, die sich auf der 
Zelloberfläche von eukaryotischen Zellen befinden. HS spielen eine wichtige Rolle 
bei der  Vermittlung und Aktivierung  verschiedener Signalwege, z.B. FGF und 
VEGF, sowie bei der Bildung von Morphogengradienten von Ihh und BMP. Zwei 
wichtige Fragen bezüglich der Entstehung von Osteochondromen blieben bisher 
ungeklärt.  
1. Was ist der zelluläre Ursprung von Exostosen? Vorangegangene  Studien 
deuten daraufhin, dass die erste Mutation, die zur Entwicklung der Neoplasie führt, 
entweder in den Chondrozyten der Wachstumsfuge oder in den Osteoblasten des 
anliegenden Perichondriums stattfindet.  
2. Welcher molekulare Mechanismus ist für die Osteochondromentwicklung  
verantwortlich? MO ist ein autosomal-dominantes Syndrom. Einerseits kann es bei 
Haploinsuffizienz zur Störung HS-abgängiger Signalwege kommen, andererseits 
kann der Verlust des noch intakten EXT-Allels in den Tumorzellen zur 
Exostosenentwicklung führen. In dieser Arbeit wurden zwei verschiedene 
Mausmodelle analysiert, um die Rolle von HS während der Entwicklung von 
Exostosen zu untersuchen. Im Gegensatz zu Ext1-/- Mäusen, die während der 
Gastrulation sterben, überleben Ext1Gt/Gt Mäuse bis kurz vor der Geburt. Ext1Gt/Gt 
produzieren ca. 20% des HS Gehalts von wildtyp Mäusen. Bisherige Studien 
zeigten, dass diese Mäuse aufgrund einer reduzierten HS-Menge eine generelle 
Verzögerung der Chondrozyten Differenzierung ausweisten (Koziel et al., 2004). In 
dieser Arbeit konnte ein zusätzlicher Effekt von HS auf die  Blutgefäßentwicklung 
identifiziert werden. In Zellkulturexperimente von Ext1Gt/Gt und wildtyp Mäusen 
würde einen Defekt bei der Produktion oder Freisetzung von VEGF-A Protein, 
welches die Gefäßneubildung aktiviert, festgestellt. In Zusammenhang mit der 
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fehlenden Blutgefäßbildung in Ext1Gt/Gt Mutanten ist die Einwanderung der 
Osteoklasten und dadurch die Knochenbildung verzögert. 
Da Ext1Gt/Gt Mäuse perinatal sterben und somit die Entwicklung der 
Osteochondrome nicht untersuchen werden können, würde eine weitere 
Mausmutante analysiert, in der das Ext1 Gen in Chondrocyten  konditional 
deletiert ist (Col2-rtTA-Cre;Ext1e2fl/e2fl). In diesen Mäusen führt eine Cre-induzierte  
Rekombination des Ext1 Gens zu einem kompletten Verlust der Ext1 Funktion. 
Col2-rtTA-Cre;Ext1e2fl/e2fl Mäuse bilden Osteochondrome in unterschiedlichen 
enchondralen Knochen des axialen und appendikulären Skeletts. Femura von 
Col2-rtTA-Cre;Ext1e2fl/e2fl Mutanten wurden in verschiedenen Stadien (zwischen 4 
und 8 Wochen) analysiert, um die Entwicklung von Osteochondromen lateral der 
Wachstumsfuge zu untersuchen. In jungen Stadien (4 bis 6 Wochen) sind 
Osteochondrome meistens chondrogen. Sie entwickeln sich aus einer kleinen 
Gruppe von Chondrozyten zu einer vielschichtigen Struktur. Diese Chondrozyten 
differenzieren in verschiedene Subpopulationen, deren  Morphologie der 
Wachstumsfuge ähnelt. Einzellclone wurden mittels Laser Mikrodissektion aus  
den Osteochondrom Gewebe isoliert und deren Genome analysiert. Ebenfalls 
wurde  ein Verlust der HS Produktion immunhistochemisch in diesem Gewebe 
nachgewiesen  
Col2-rtTA-Cre;Ext1e2fl/e2fl Mäusen zeigen zusätzlich typische Symptome einer 
Osteoarthrose, welche mit dem enzymatischen Abbau von Proteoglycanen 
einhergeht. 
In dieser Arbeit konnte eine Chondrozytenpopulation der Wachstumsfuge als 
Ursprungszellart des Osteochondroms identifiziert werden. Der Verlust der 
Heterozygotizität in diesen distalen Chondrozyten ist die Ursache von MO 
Syndrom. Diese Chondrozyten proliferieren und differenzieren in eine Struktur, die 
Ähnlichkeiten mit der Wachstumsfuge aufweist. Zusätzlich können die Col2-rtTA-
Cre;Ext1e2fl/e2fl  Mutanten  als nützliches Modelsystem bei der Untersuchung der 
Entstehung von Osteoarthrosen dienen. 
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9. Abbreviations 
ACH   Achondroplasia 
Agc1   Aggrecan1 
AgNO3   Silver nitrate 
ß2M   Beta-2-microglobulin 
β-gal   β-Galactosidase 
Bglap   Bone Gla protein 
BMPs   Bone morphogenetic proteins 
bp   Basepair(s) 
BSA   Bovine serum albumin 
C   Celsius 
CaCl2   Calcium cloride 
cm   Centimeter 
CO2   Carbon dioxide 
Col    Collagen 
Cre   Cre recombinase 
CS    Chondroitin sulfates  
CT-value   Fluorescence threshold value 
DAB   Diaminobenzidine substrate 
DEPC   Diethylpyrocarbonat 
DMSO  Dimethylsulfoxid 
DNA   Deoxyribonucleic acid 
Abbreviations 
121 
 
dNTPs  Desoxyribonukleotidtriphosphat (dATP, dTTP, dCTP, dGTP) 
DPX   Di-n-butylPhthalate 
DZ   Deep Zone 
E    Embryonic day 
ECM   Extracellular matrix 
EDTA   Ethylendiamintetraacetate 
EtOH   Ethanol 
Ext   Exostosin 
FCS   fetal calf serum 
FGF   fibroblast growth factor 
FGFR   FGF receptor 
Flt1   Fms-like tyrosine kinase receptor1  
KDR   kinase insert domain-containing receptor 
Flk1    Fetal liver kinase 1  
fw   Forward 
GAG    Glycosaminoglycan  
Gal    Galactose 
Gbw   gram body weight 
GDF    Growth/differentiation factor  
GFP    Green fluorescent protein 
GlcA    D-glucuronic acid  
GlcNAc   N-acetyl-D-glucosamine 
Gly   Glycerol 
H2O2   Hydrogen Peroxyde 
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H&E   Hematoxylin/Eosin 
HA   Hyaluronan 
HSPG   Heparan sulfate proteoglycan 
HS   Heparan sulfate  
HRP   Horseradish peroxidase 
Hspg2  Perlecan 
IdoA   Iduronic acid 
Ig   Immunoglobulin 
Ihh   Indian hedgehog 
Kb   Kilobasepairs 
KDa   Kilodalton 
KOH   Potassium hydroxyde 
LB   Luria Bertani  
LCM   Laser capture microdissection 
LiCl   Litium cloride 
LOH   Loss of heterozygosity 
M   Molar 
mg   Milligram 
MgCl2  Magnesium cloride 
ml   Milliliter 
Mmp   Matrix metalloprotease  
MO    Multiple osteochondromas  
MZ   Middle zone 
n   Nano  
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n   Number 
NaCl   Sodium cloride 
NaOH   Sodium hydroxide 
NEO   Neomycin 
Nrp   Neuropilin 
OA    Osteoarthritis  
OD   Optical density 
O/N   Over night 
Osc   Bglap, Bone Gla protein 1 
P   Postnatal day 
p   Chromosome short arm 
PBS   Phosphat Buffered Saline 
PECAM1  Platelet endothelial cell adhesion molecule 1 
Pen/Strep  Penicillin/Streptomycin 
PFA   Paraformaldehyde 
pH Negative logarithm base 10 of the molar concentration of 
dissolved hydronium ions 
pg Picogram 
PTHrP  Parathyroid hormone (PTH) related protein 
PTCH1  Patched-1 
PPR   PTH/PTHrP receptor 
q   Chromosome long arm 
qRT-PCR  Quantitative reverse transcription polymerase chain reaction 
RA   Rheumatoid arthritis 
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RNA   ribonucleic acid  
Rpm   Revolution per minute 
RT   Room temperature 
rtTA   Tetracycline reverse transcriptional activator 
RTK   Receptor tyrosin kinase 
Rv   Reverse 
SSC   Standard saline citrate 
SZ   Superficial zone 
Taq   Termus aquaticus 
TD   Thanatophoric dysplasia 
TRAP   Tartrate resistant acid phosphatase 
U   Unit 
UCMA  Unique cartilage matrix-associated protein 
UV   Ultra violet 
X   Times 
Xyl   Xylose 
V   Volume 
VEGF   Vascular endothelial growth factor 
VEGF-A  Vascular endothelial growth factor (Mouse protein) 
Vegf-A  Vascular endothelial growth factor (Mouse gene) 
VEGFR  VEGF receptor 
Wt   Wild type 
µ   Micro- 
µCi   Microcurie 
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